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ABSTRACT 
 
Nanotechnology has been the subject of significant scientific and biomedical 
development efforts over the past decades. Improvement in biomarker discovery, targeting 
approaches and conjugation chemistries has led to the development of many novel nanomaterials 
for individualized therapy.  In this thesis, we investigate a new class of nanomaterial called 
“nanofiber precursor” (NFP). The NFP is composed of multiple self-assembling peptides via 
electrostatic and non-covalent interactions.  Each peptide consisted of β-sheet sequence attached 
to a methoxypolyethylene glycol (mPEG) via a linker. By conjugating either near infrared 
fluorophore or therapeutic antibodies, we demonstrate the application of NFP in diagnosis and 
therapy of cancer respectively. The main objectives of this thesis are:  (1) To design and 
synthesize a near infrared nanofiber for imaging urokinase plasminogen activator (uPA) activity 
(2) To develop a Herceptin-conjugated nanofiber as multivalent targeted system for increasing 
therapeutic efficacy of Herceptin, a monoclonal antibody used for breast cancer treatment. We 
were successful in conjugating near infrared dye NIR664 to the nanofiber as well as Herceptin 
on the surface of nanofiber. (1) The NIR-NFP conjugate could detect recombinant uPA activity 
with sensitivity of 3 ng. (2) The Herceptin-conjugated nanofiber (HER-NFP) was more than two 
fold effective in inhibiting growth of HER-2 positive cells. In the second half of the thesis, we 
have also investigated tumorigenic role of 15-LOX-1, a lipid peroxidizing enzyme in prostate 
cancer. The aim of this study was: (3) To investigate the role of 15-lipoxygenase-1 (15-LOX-1) 
in upregulation of uPA in PC-3 prostate cancer cells. As a whole, the research presented in this 
thesis is aimed at designing new strategies and understanding molecular mechanisms that lead to 
prevention and treatment of cancer. 
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CHAPTER 1. STATEMENT OF PROBLEM AND RESEARCH OBJECTIVES 
Cancer is the second most common cause of death in the US, exceeded only by heart 
disease, accounting for nearly 1 of every 4 deaths [1]. According to the American cancer society, 
about 577,190 Americans are expected to die of cancer in the year 2012. Among all strategies 
explored, use of nanotechnology has been proven to useful in many aspects of cancer treatment 
and prevention [2, 3]. 
Today, nanomaterial are extensively used in designing sensors [4], imaging contrast 
agents [5, 6], platforms for localized delivery and therapy [7, 8], and development of research 
tools for understanding the biology of cancer [9, 10]. The primary objective of this thesis is to 
investigate the potential applications of new type of peptide based nanomaterial known as 
“nanofiber precursor” for diagnosis and treatment of cancer [11-13]. This thesis is divided into 
three chapters, in which the first two chapters are focused on the application of peptide nanofiber 
precursor (NFP) for either imaging or therapy via conjugation of near infrared fluorophore and, 
therapeutic antibodies respectively. The third chapter focuses on a different study in which we 
discuss a new role of a lipid oxidizing enzyme 15-lipoxygenase-1 (15-LOX-1) in tumorigenesis 
of prostate cancer mediated by upregulation of uPA. The detailed description of individual 
chapters is discussed below: 
In the first chapter, we discuss the application of nanofiber for imaging urokinase 
plasminogen activator (uPA) [8]. uPA is a clinically validated biomarker for predicting patient 
prognosis as it is found to be overexpressed in various cancers [14] including breast [15], 
prostate [16], renal [17], ovarian [18], cervical [19], pancreatic [20], glioma [21], colorectal [22], 
and gastric cancers [23]. Since a majority of cancer deaths are due to metastasis, determining 
level of uPA in tumors is important for predicting metastatic potential of the tumor and helps us 
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in identifying the subset of patients requiring chemotherapy [15, 24, 25]. Unfortunately, the 
currently available methods such as ELISA and IHC for determining uPA level in tumors rely on 
biopsy or surgical invasion [26-29]. Therefore, there are efforts needed towards in vivo protease 
imaging which will be convenient for patients as they do not have to undergo invasive surgeries. 
Moreover, current technologies rely only on determining levels of uPA, instead of activities. My 
work is extension of previously designed a peptide-based, self-assembly nanofiber precursor 
(NFP) for detecting uPA activity [12, 13]. In the previously described NFP, FITC was employed 
as an optical reporter [30]. However, the fluorescence emission in the visible wavelength (at 485 
nm) limits its use for in vivo imaging [31]. In order make NFP applicable for in vivo imaging, an 
important feature would be to utilize a near infrared fluorophore in the construction of this probe. 
Near infrared dyes provide better contrast as they fluoresce in region where there is no 
interference from biological tissues [32, 33]. To this end, the first chapter in this thesis is focused 
on the design and synthesis of near infrared nanofiber (NIR-NFP) for imaging uPA. We believe 
that results obtained from this study will help in designing biomarker based strategies and 
ultimately be beneficial in prognosis, prediction, screening of disease, and monitoring therapy in 
patients.  
In chapter 1, we proposed the following hypotheses: 
1. A near infrared nanofiber (NIR-NFP) can be successfully designed and synthesized. 
2. The NIR-NFP will have nanoscale dimensions and its fluorescence intensity will be 
quenched due to close placement of near infrared dyes on its structure.  
3. Due to the presence of methoxy polyethylene glycol molecules (mPEG), the nanofiber 
will be homogeneous preparation. 
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4. Upon incubation of recombinant uPA activity in vitro, the nanofiber will increase near 
infrared fluorescence signal. The increase in fluorescence signal will be accompanied by 
conversion of nanofiber into interfibril network. 
5. The nanofiber can detect uPA secreted from cancer cells. The increase in fluorescence 
signal will correlate to level of uPA level in the cell lines, which can be further confirmed 
using commercial uPA activity assay kit. 
The proposed hypotheses were tested by designing the following specific aims:  
 To design, synthesize and perform in vitro characterization of NIR-NFP.  In order to 
achieve this, the previously reported peptide construct (mPEG-BK(FITC)-SGRSANA-
[kldl]3) will be modified by replacing the FITC with a near infrared fluorophore 
(NIR664).  
 To characterize the NIR-NFP by UV spectroscopy, fluorescence spectroscopy and 
transmission electron microscopy (TEM).  
 To investigate whether NIR-NFP can detect cell-secreted uPA and, whether NFP is able 
to differentiate cancer cell lines based on different expression of uPA. 
This study is intended to answer the following questions: 
1. Can NIR-NFP detect recombinant and cell-secreted uPA? If so, is it sensitive enough to 
detect clinically relevant levels of uPA? 
2. Does the increase in fluorescence intensities correlate with structural changes in 
nanofiber? 
In chapter II, we discuss the application of nanofiber for increasing the therapeutic 
efficacy of Herceptin, a monoclonal antibody used in the treatment of breast cancer [34].  
Monoclonal antibodies have entered an era in which they are increasingly becoming the 
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treatment of choice for cancer because of advantages such as less side-effects and higher 
specificity as compared to chemotherapeutic drugs [35, 36]. However, their clinical response rate 
is modest and development of resistance occurs in some cases [37-40]. Therefore, new formats 
of antibodies with modiﬁed properties have been generated to improve the therapeutic efficacy 
of monoclonal antibodies [41]. Among all strategies investigated, multivalency approach has 
provided meaningful improvements in clinical activity over unconjugated antibodies [42, 43]. 
“Multivalency” means essentially means a state of having valency of more than two. Multivalent 
antibodies are known to have higher functional afﬁnity [44], lower dissociation rates when bound 
to cell-surface antigens, and enhanced biodistribution and pharmacokinetic profiles [45]. In the 
present study, we employed a previously described nanofiber precursor (NFP) [12, 13] as a 
multivalent platform to improve the cytotoxicity of a monoclonal antibody against epidermal 
growth factor receptor 2 (HER-2), a receptor that is overexpressed in 20 to 30% of breast cancer 
patients [46-48]. NFP was a two-dimensional monolayer assembled from multiple self-
assembling peptides via electrostatic and non-covalent interactions [49, 50]. 
In chapter two, we proposed the following hypotheses: 
1. Herceptin-conjugated NFP (HER-NFP) will be more effective in inhibiting cell growth as 
compared to Herceptin alone. 
2. The mechanism of cell growth inhibition will be accompanied by downregulation of 
signal transduction pathway associated with HER-2 receptor.  
The proposed hypotheses were tested by designing the following specific aims:  
 Design and synthesis of Herceptin-conjugated nanofibers (HER-NFP). Each peptide will 
consist of β-sheet sequence (kldlkldlkldl, where k, l, and d were in D-configurations) 
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attached to a methoxypolyethylene glycol (mPEG) via a linker (SGASNRA) to prevent 
aggregation. 
 To perform covalent conjugation of Herceptin antibodies on the surface of nanofibers by 
sodium periodate method [51]. Multiple antibodies against HER-2 (Herceptin) will be 
conjugated to the NFP surface at the surface -NH2 functional groups contributed by the 
side chains of the lysine residues. 
 To characterize the HER-NFP loading by UV spectroscopy, electrophoreses and 
transmission electron microscopy (TEM). 
 To investigate the influence of different loading density of Herceptin on rate and intensity 
of cellular uptake of HER-NFP in HER-2 overexpressing SKBr-3 cells 
 To determine specificity of HER-NFP in cancer cells exhibiting different levels of HER-2 
receptor. 
 To investigate the mechanism involved in increasing the therapeutic efficacy of 
Herceptin by activation status of proteins of cell survival pathways, mainly 
phosphatidylinositol 3-kinase (PI3K) and mitogen activated protein kinase (MAPK) 
pathways.  
This study was intended to answer the following questions: 
1. Is HER-NFP is more efficacious in inhibiting cell growth as compared to Herceptin alone 
in HER-2 overexpressing cancer cells? 
2. Will there be changes in cellular uptake, cellular distribution and HER-2 receptor 
signaling when multiple Herceptin antibodies are conjugated to nanofiber? If so, how will 
it compare to unconjugated Herceptin? 
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In the third chapter, we are investigated the role of a lipid-peroxidizing enzyme, 15-
lipoxygenase-1 (15-LOX-1), in the expression of urokinase plasminogen activator (uPA) in 
prostate cancer. It is known that metastases mediated by proteases are one of the main causes of 
death due to prostate cancer [52, 53]. Several epidemiologic studies have revealed that there may 
be association between dietary lipids and progression of prostate cancer [54-58]. However, there 
is no published data on the relationship between lipid metabolism and metastatic progression 
mediated by proteases among prostate cancer patients. Among the large families of lipid 
peroxidising enzymes, 15-LOX-1 is particularly interesting enzyme, which has been implicated 
to have a strong tumorigenic role in prostate cancer [59-62]. In this study, our aim was to study 
the relationship between 15-LOX-1 and urokinase plasminogen activator, a validated marker for 
metastasis [63, 64]. We believe that this study is important because it provides understanding 
how diet control may prevent onset for metastatic progression of cancer. 
In chapter three, we proposed the following hypotheses: 
1. 15-LOX-1 in PC-3 prostate cancer cells is involved in the upregulation of uPA level. 
Normal prostate cancer cells (PC-3 cells) transfected with 15-LOX-1 (15-LOX-1/PC-3 
cells) will lead to upregulation of uPA as compared to their parental controls. On the 
other hand, knockdown of 15-LOX-1 using siRNA transfection in 15-LOX-1/PC-3 cells 
may lead to downregulation of uPA. 
2. 15-LOX-1/PC-3 cells will demonstrate enhanced migratory potential and wound healing 
ability as compared to parental PC-3 cells. 
3. 15-LOX-1/PC-3 cells will demonstate higher levels of activated forms of members of 
MAPK family as compared to PC-3 cells. Since MAPK pathway is central mechanism 
that regulates the level of uPA, we hypothesize that it may serve as an intermediatory 
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pathway involved in the signaling between 15-LOX-1 and uPA. We also hypothesize that 
incubation with specific inhibitors of MAPK subfamilies will decrease the levels of uPA 
in both PC-3 cells and 15-LOX-1/PC-3 cells. 
The proposed hypotheses were tested by designing the following specific aims:  
 To investigate whether overexpression of 15-LOX-1 may lead to upregulation of uPA in 
PC-3 cells 
 To investigate whether mitogen-activated protein kinase (MAPK) pathway is involved in 
the upregulation of uPA in 15-LOX-1/PC-3 cells.  
 To investigate whether increases migratory ability and wound healing ability of 15-LOX-
1/PC-3 cells 
This study is intended to answer the following questions: 
1. Does there any relationship exist between 15-LOX-1 and uPA in prostate cancer?  
2. Can induction of 15-LOX-1 in prostate cancer cells lead to enhanced migration and 
wound healing ability? 
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CHAPTER 2. DESIGN AND SYNTHESIS OF A NEAR-INFRARED FLUORESCENT 
NANOFIBER PRECURSOR FOR IMAGING UROKINASE ACTIVITY 
2.1. Abstract 
Abnormal proteolysis is often observed during disease progression. Up-regulation of 
certain tumor-associated proteases such as urokinase plasminogen activator (uPA) can be a 
biomarker of malignant transformation. In this chapter, we report the design and synthesis of a 
near infrared (NIR) nanofiber precursor (NIR-NFP) for detection of uPA activity. NIR-NFP, 
which is optically silent in its native state, is composed of multiple self-assembled peptide units 
(PEG54-BK(NIR664)SGRSANA-kldlkldlkldl-CONH2). Upon uPA activation, NIR-NFP releases 
peptide fragments that contribute to significant fluorescence amplifications at 684 nm. The NIR-
NFP was able to detect uPA activity in culture media obtained from uPA-overexpressing cancer 
cell lines (SKOV-3, MCF-7, MDA-MB-231, PANC-1, PC-3, and HT-1080). Fluorescence 
changes were uPA dependent, and the results were as comparable with both western blot analysis 
and enzyme activity assay. Our data suggests that the optimized NIR-NFP preparation may be 
useful for imaging uPA activity in vivo.  
2.2. Introduction 
2.2.1. Biomarkers for cancer  
Biomarkers are increasingly becoming important tools for understanding a wide range of 
diseases through randomized clinical trials, epidemiology studies, screening, diagnosis and 
prognosis [65-67].  In cancer research, there is ongoing research to identify new biomarkers that 
can be used for early screening and/or detection, designing personalized therapies, and 
understanding mechanisms that are involved in the progression of disease [68, 69]. Examples of 
some clinically relevant biomarkers are summarized in Table 1. 
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Table 1. Examples of clinically relevant biomarkers. 
Biomarker Cancer Reference 
Alpha-foetoprotein Hepatocellular 
carcinoma 
[70] 
APC gene Adenocarcinoma  [71] 
HER-2/neu gene Breast cancer  [72] 
Prostate specific antigen (PSA) Prostate cancer  [73] 
Urokinase plasminogen activator (uPA) Breast cancer  [15] 
S100 protein Melanoma  [74] 
CA-125  Ovarian cancer  [75] 
Heat shock proteins (Hsp27& Hsp27) Prostate cancer  [76] 
Human chorionic gonadotrophin (hCG) Ovarian cancer  [77] 
 
Biomarkers can be constituents of tissues or body fluids, and their levels detected help 
clinicians in discriminating disease condition versus normal condition [78]. For example, 
urokinase plasminogen activator (uPA), a serine protease and its inhibitor PAI1 are validated 
diagnostic and prognostic biomarkers for breast cancer [79]. Likewise, another serine protease 
PSA (prostate-specific antigen), has been the major diagnostic marker for prostate cancer [80]. 
The levels of these biomarkers are normally found to be low in their serum, however become 
increased in cancer conditions. By determining the exact level of biomarker, clinicians are able 
to select optimal adjuvant treatment for therapy on the basis of the nature and stage of disease.  
Biomarkers are identified from epidemiological investigation [81, 82]. Advancement in 
genomics and proteomic technologies allows large number of survival pathways to be screened 
simultaneously. For example, simultaneous analyses of genes can be achieved by microarray- or 
sequencing-based technologies in same sample set [83]. Likewise, different protein expressions 
in the sample set can be analyzed by MALDI-MS maintenance [84]. Such information is useful 
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for understanding of complex mechanisms that play important role in cancer development [85, 
86]. The successful discovery and validation of biomarkers also depends on factors such as data 
handling, sample processing, statistical analysis, and therefore is a colloaborative effort which is 
contributed by clinicians, statisticians, scientists.  
2.2.2. Proteases as biomarkers 
Proteases are an important class of enzymes which regulate a variety of functions and can 
be classified into six groups: serine, cysteine, aspartate, glutamic acid, threonine, and 
metalloproteases, depending on the structure of catalytic site and presence of amino acid 
essential for activity [87-91]. They are vital for maintaining normal physiological processes such 
as cell proliferation, cell replication and apoptosis, tissue wound healing, coagulation and 
respond to specific stimuli. For example, proteases such as pepsin and trypsin are secreted to 
improve digestion in the stomach [92]. Likewise, proteases such as plasmin and thrombin play 
important role in blood clotting [93]. Other proteases such as cathepsins are located in the 
leukocytes and contribute to regulation of immune response [94]. Given their roles in various 
conditions, proteases have emerged as prognostic or diagnostic marker diseases such as digestion 
disorders, inflammatory conditions, and immunity and blood flow disorders [95].  There are 
several new technologies being developed to detect proteases for early screening of deseases, 
drug targeting, and therapeutics.  
2.2.3. Existing technologies for detecting biomarkers  
Various types of assays are used to measure proteins in complex biological samples [96]. 
Current techniques for protein biomarkers discovery and profiling include mass spectroscopy, 
electrophoreses, and immunological assays such as enzyme-linked immunosorbent assay 
(ELISA), and western blotting are described in the following sections: 
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2.2.3.1. Polyacrylamide gel electrophoresis 
One- or two-dimensional sodium dodecyl sulfate polyacryamide gel electrophoresis (1D 
or 2D SDS PAGE) has been available for several decades for the quantitation and identification 
of proteins. This method relies on separation of proteins on the basis of isoelectric point (pI) and 
molecular weight [97-99], and allows different proteins in complex biological system can be 
resolved and compared. However, the only limitation of 2D SDS PAGE is that it cannot resolve 
proteins in conditions when proteins are smaller than 10 kDa or too basic [100]. 
2.2.3.2. Mass spectroscopy 
Mass spectrometry (MS) based assays have been available for several decades for 
biomarker identification and characterization. The main advantages of this technique over 
antibody-based methods are its less cost, time-effective, and specific [101], and is therefore an 
attractive alternative to antibody based assay when desired antibody is not available. This 
method has advantage that it requires minimal sample processing and that it can analyze a large 
number of samples in a short time [102, 103]. However, one limitation of MS is that only small 
proteins can be analyzed using this method [104]. 
2.2.3.3. Western blot 
Western blot is widely used for assessing protein levels in in serum, tissues, and organs 
and commonly used in laboratory practices [105]. Its main advantage is that it is relatively 
inexpensive procedure; however not FDA is approved methods for clinically determining 
biomarker levels [106]. Few limitations of western blot are its semi-quantitative nature, time-
consuming and resource-intensive nature and cannot practically be undertaken for many proteins 
[107]. 
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2.2.3.4. Immunohistochemistry (IHC) 
Immunohistochemistry (IHC) is the method of choice for tissues, especially when a 
protein is the target [108]. It is FDA approved method and widely used in clinics and relatively 
inexpensive. It is especially advantageous when the proteins undergo posttranslational 
modification such as phosphorylation [109]. However, this method is semiquantitative in nature, 
and requires well trained pathologists to interpret grading of tumor. 
2.2.3.5. Enzyme-linked immunosorbent assay (ELISA) 
ELISA has been traditional method for biomarker discovery and validation, and it still 
considered to be a “golden standard” for detection of protein in clinical tests and multicenter 
prospective and randomized studies [110-112]. It is highly sensitive method for detecting 
proteins; however, its limitation is that sometimes desired antibodies are not available for the 
target under investigation. 
2.2.4. Optical imaging  
Various molecular techniques have been used to image proteases including magnetic 
resonance imaging (MRI), positron emission tomography (PET), and single photon emission 
computer tomography (SPECT) [113-117]. Imaging of proteases is becoming an important 
strategy for developing new anti-cancer therapies [118-120]. Proteases play crucial roles in the 
progression of cancer by facilitating invasion of the extracellular matrix, cell proliferation, and 
angiogenesis. Therefore, imaging protease activity may be a useful tool in biomedical 
applications such as detection of early-stage tumors and metastases [121-123].  
Majority of the probe used for optical detection of proteases rely on the change of their 
optical properties after protease cleavage, and thus are commonly referred as “smart probes” or 
“activatable probes” [124, 125]. In native stage, the probe is typically designed to be maximally 
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quenched by placement of fluorophore and quencher (same or another fluorophore dye) in close 
proximity because of fluorescence resonance energy transfer (FRET). [126-128]. Cleavage of the 
protease substrate separates the fluorophore and the quencher resulting in the enhancement of 
fluorescent signal. Therefore, “activatable probes” can be designed which have little or no 
optical signal in the inactive state but generate signal after interacting with molecular target [122, 
129, 130]. More than a decade ago, the first in vivo optical imaging probe was developed for 
detecting activity of cathepsin B in in a xenograft lung carcinoma [131]. The probe consisted of 
multiple near-infrared fluorophores conjugated to long circulating graft copolymer consisting of 
poly-L-lysine and methoxypolyethylene glycol succinate. Due to their close proximity, the 
fluorophores were optically quenched. Following intravenous injection, the probe accumulated in 
tumor as a result of enhanced permeability and retention effect (EPR). In vivo imaging revealed 
a 12-fold increase in the NIRF signal, allowing the detection of submillimeter-sized tumors 
[131]. 
Recently, near infrared imaging has been valuable for non-invasive detection of 
proteases and other molecules. Biological tissues such as water, lipids, and hemoglobin, 
generate auto fluorescence because they absorb in the visible range (350-700 nm) [31, 132]. 
NIR probes offer higher sensitivity and efficiency because they absorb light in near-infrared 
part of the spectrum (700-1000 nm). They offer higher target to background ratio, and optical 
signal at depths of 7-14 cm may be achieved using NIRF probes. In small animals, a variety 
of NIRF dyes such as Cy5.5, indocyanine green, and Alexa dyes have been used [133-135]. 
Besides using dye molecules, near infrared imaging has also been performed using 
nanomaterial such as quantum dots; however, their potential toxicity may limit their 
applications in patients [136, 137].  
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2.2.5. Near infrared dyes for optical imaging 
The synthesis of NIR dyes is gaining a great deal of attention due to their wide 
application in various fields such as biomedical research and material sciences [138-141]. The 
NIR dyes can be broadly classified according to their core structures and include 
phthaocyanines, cyanines, and squarine dyes [142, 143]. Several modifications are being 
performed in the structure of NIR dyes to improve their photochemical and photophysical 
properties. For example, functional groups such as sulfonate, carboxylate, and pyridinium 
have been conjugated to the core structure of the NIR dye to increase solubility [144, 145]. 
Cyanine dye fluorophore belongs to a family of dyes which contain a heterocyclic ring such 
as an indole, quinolone, or isoquinoline and benzooxazole as well as an unsaturated carbon 
chain.  
The structure and positions of functional groups the heterocyclic rings and the length 
of the carbon chain govern the photochemical and photophysical properties of the dye [146], 
such as fine tuning the excitation wavelength, emission wavelength, solubility, and stability 
[147, 148]. For example, the color of the dye and the emission wavelength can be changed by 
modification of the polymethine moieties bridging the heterocyclic ring system [149]. 
Furthermore, these dyes can be further modified with succinimidyl esters as reactive 
functional groups to allow the conjugation to biologically active moieties such as antibodies, 
DNA, and proteins [150, 151]. Till now, the only FDA approved dye is iodocyanine green, a 
water soluble cyanine dye, which is clinically used in applications such as ophthalmic 
angiography, determination of cardiac output and liver function [152-154]. Some of the 
examples of the currently used near infrared dye molecules are shown in Fig. 1. 
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Fig. 1. Structures of commonly used near infrared dyes. 
 
2.2.6. Nanomaterial for near infrared imaging  
Various nanomaterials are used for near infrared imaging [140, 155-158]. The dyes 
may be encapsulated in the core of the nanoparticle or conjugated on its surface. 
Encapsulation of dyes in the core of the nanoparticle or surface conjugation may be 
advantageous for the purpose of in vivo imaging due to the following reasons. Firstly; the dye 
is protected from the outside environment which may lead to either degradation of the dye or 
quenching of the fluorescence. Secondly, a high payload of dye may be encapsulated within 
the core of the nanomaterial which may boost the fluorescence signal and sensitivity for 
detection. [159-161]. Examples of nanoparticles used for various imaging applications are 
listed in Table 2.  
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Table 2. Various nanomaterials used as probes for near infrared imaging. 
Furthermore, biologically reactive moieties may be conjugated to the surface of the 
nanomaterial through reactive functional groups of the shell which may improve in targeting 
For example, various ligands such as antibodies [171, 172], peptides [173], folic acid [163], 
polysaccharides [174], and oligonuclides have been conjugated to dye containing 
nanoparticles. ICG has been commonly employed dye for purpose of encapsulation since it is 
approved by FDA [175-177]. Poly (D, L-lactic-co-glycolic acid) (PLGA) nanoparticles 
entrapping ICG increased the deposition of ICG in organs upto 2-8 as compared to free ICG 
[178].  
NPs Core 
material 
Synthesis Properties Reference 
Silica NPs Amorphous 
Silica 
Microemulsion 
 
Biocompatible and 
amenable to 
conjugation 
 
 [162, 163] 
Calcium 
Phosphate NPs 
Calcium 
Phosphate 
Double 
emulsion 
Effective for 
targeted drug and 
gene delivery, safe 
and stable 
[164, 165] 
Lipoprotein 
NPs 
Low Density 
Lipoprotein 
(LDL) 
Microemulsion Biodegradable and 
high payload 
capacity 
 [166] 
Quantum Dots Semi-
conductor 
Elements 
Organic 
synthesis 
Aqueous 
synthesis 
Broad absorption 
spectrum, high 
extinction 
coefficient, 
resistant to 
photobleaching 
 [167, 168] 
Upconversion 
NPs 
Rare Earth 
Elements 
Thermal 
decomposition 
Can be excited by 
IR radiation due to 
upconversion 
 [169, 170] 
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Silica nanoparticles are also commonly used for fluorescence imaging [175, 179]. Dye 
containing silica nanoparticles, also commonly referred as “nanodot” have been used for 
imaging of metastatic progession to lymph nodes has been investigated in clinical trials for 
diagnosis and staging of advanced melanoma [180]. Besides imaging, several nanoparticles 
are also used for intracellular sensing [181-183].  
2.2.7. Optical imaging of protease activity 
One unique feature of fluorescence imaging is that probes can be designed to be optically 
quenched in their native state and can be activated by interacting with the target [184, 185]. 
Therefore, activatable probes can be designed which have little or no optical signal in the 
inactive state but generate signal after interacting with molecular target [122, 129, 130]. Some 
examples of optical imaging of proteases are summarized below (Table 3): 
Table 3. Examples of proteases used for optical imaging of various diseases. 
 
Target protease Disease Substrate Reference 
Cathepsin B Cancer KK [131] 
Cathepsin D Breast cancer PICFF [186] 
MMP-2 Metastases PLGVRG [187] 
Caspase-3 Apoptosis DEVD [188] 
Thrombin Cardiovascular F(Pip)RS [189] 
uPA Cancer GGSGRSANAKC-NH2 [12] 
MMP-3 Arthritis Polymeric probe [190] 
MMP-13 Osteoarthritis GPLGMRGLGK [191] 
2.2.8. Urokinase as biomarker  
The urokinase plasminogen activator (uPA) is a serine protease that plays an important 
role in tumor-associated proteolysis.  The enzyme initiates the catalytic conversion of inactive 
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zymogen plasminogen to the active plasmin [192]. This conversion can further (1) facilitate 
cancer metastasis by degrading the extracellular matrix and basement membrane [193] and (2) 
activate certain MMP’s precursors [194] as well as specific growth factors, such as transforming 
factor-β (TGF-β), fibroblast growth factor-2 (FGF-2), and insulin-like growth factor 1 (IGF-1) 
[195] (Fig. 2).
 
Fig. 2. Various pathological roles of urokinase plasminogen activator (uPA). 
 
Overexpression of uPA can be found in various types of cancers [14] including breast 
[15], prostate [16], renal [17], ovarian [18], cervical [19], pancreatic [20], glioma [21], colorectal 
[22], and gastric cancers [23]. Particularly in breast cancer, the overexpression of uPA and its 
natural inhibitor urokinase plasminogen activator inhibitor-1 (PAI-1) is associated with poor 
patient prognosis [15]; this has been studied in multicenter prospective clinical trials, meta-
analysis and both retrospective and prospective studies [24, 196, 197]. 
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2.2.9. Optical imaging of tumor-associated uPA activity 
2.2.9.1. Using grafted polymer 
The development of the first uPA-activatable NIRF imaging probe was reported in 
year 2004 [12]. The probe consisted of a uPA cleavable motif (GGSGRSANA) terminally 
capped with NIR fluorophores and a polymethylene glycol (PEG) poly-L-lysine grafted co-
polymer (Fig. 3). As shown in the figure, upon addition of recombinant human uPA, there 
was 680% amplification of fluorescence signal observed. The probe was able to discriminate 
cancer cell lines based on the high level (HT-1080) and low level (HT-29) of uPA. In vivo 
studies performed in nude mice indicated that there were up to three-fold increases in uPA-
overexpressing tumors as compared to the control tumors [12]. 
 
 
Fig. 3. Schematic diagram showing the design of an uPA-sensitive grafted polymer probe. The 
probe consisted of a peptide substrate (GGSGRSANA) terminally conjugated to fluorophore and 
a polymethylene glycol (PEG) poly-L-lysine backbone. The close proximity of fluorophores 
resulted in fluorescence quenching.Upon the addition of uPA, the enzyme digests the probe, 
subsequently releasing the free dye-conjugated fragments, resulting in fluorescence 
amplification. 
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2.2.9.2. Peptide-based matrix 
Protease-responsive peptide matrices have been used for the detection of uPA [26, 
198]. The backbone of the peptide matrix is essentially composed of the self-assembly peptide 
KLDL-12 (Ac-KLDLKLDLKLDL) which is able to form a self-assembled matrix via β-sheet 
interaction molded in a casting frame [199, 200].  In the presence of uPA, cleavage of the 
peptide substrate in the matrix takes place, resulting in weakening of the matrix. The 
degradation of matrix could be monitored by release of fluorescence which was covalently 
conjugated to the N-terminus of the peptide. Additionally, a cytotoxic peptide (r7-kla) was 
incorporated into the matrix which could be triggered to release by uPA.  
2.2.9.3. Using protease sensitive nanofiber 
Nanomaterial may alternately used for detection of proteases. A modification of 
previous strategy was performed by the same group in which self-assembly sequence (kldl)3 
[201] was conjugated to a uPA clevable substrate (SGRSANA) [202], hydrophilic 
polyethylene glycol (PEG), and a fluorophore (FITC). The sequence of individual peptide 
construct was mPEG-BK(FITC)-SGRSANA-[kldl]3 [13]. In aqueous solution, the presence of 
PEG prevented the formation of inter-fibril networking and resulted in the formation of 
homogeneous nanofibers. Upon exposure to uPA, there was cleavage of substrate and release 
of fluorescence signal [203]. 
2.2.10. Imaging uPA activity 
The amount of uPA in tumor extract can be determined by enzyme-linked 
immunosorbent assay (ELISA) [27, 28] or by immunohistochemistry (IHC) [29]. Commercial 
ELISA kits are available for identifying the subgroup of cancer patients who will benefit from 
adjuvant therapy [25]. A clinical cut-off value (3 ng of uPA per mg of protein) found in the 
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tumor extract is normally utilized for classifying the at-risk patient groups [204]. For example, 
lymph-node-negative patients with low uPA levels (<3 ng/mg) are candidates for avoiding the 
burden of adjuvant chemotherapy [204]. On the other hand, patients with high uPA levels (>3 
ng/mg) can be benefit from the treatment [25]. Although ELISA is a golden standard for 
determining uPA levels, this technique is confined to in vitro analysis. Moreover, it detects only 
the level of uPA, instead of its activity. 
2.2.11. What are the advantages of using near infrared (NIR) nanofiber? 
Nanomaterials derived from self-assembly peptides can provide a high degree of 
flexibility to be modified into bioresponsive materials [205]. These materials are normally 
constructed with β-sheet peptides, and can be self-assembled to form hydrogels via ionic and 
non-covalent interaction [206], which has been used for tissue engineering [207] and drug 
delivery [208]. A peptide-based self-assembled nanofiber precursor (NFP) for detecting uPA 
activity was previously described [13]. FITC was employed as an optical reporter. However, the 
fluorescence emission in the visible wavelength (at 485 nm) limits its use for in vivo imaging 
[115]. Our aim in this study was to design a second generation NFP. The previously reported 
peptide construct (mPEG-BK(FITC)-SGRSANA-[kldl]3) could be modified by replacing the 
FITC with a near infrared fluorophore (NIR664). In addition, two homogeneous polyethylene 
glycols (PEG), instead of one heterogeneous methoxyl PEG (mPEG) could be conjugated at the 
peptide N-terminus. As a result, the peptide could be synthesized as a homogenous moiety.  
2.3. Experimental procedures 
2.3.1. Chemicals 
All amino acids used for peptide synthesis were purchased from Protein Technologies 
(Tucson, AZ). Fmoc-NH-(PEG)27-COOH and Boc-NH-(PEG)27-COOH were purchased from 
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Novabiochem (San Diego, CA). Thioanisole and ethanedithiol were acquired from Alfa Aaeser 
(Ward Hill, MA).  Anisole was purchased from TCI America (Portland, OR).  NIR-664-N-
succinimidyl ester (NIR-664-NHS) was purchased from Fluka (Milwaukee, WI). uPA (urokinase 
from human urine) and PSA (prostate specific antigen) were purchased from Sigma Aldrich (St. 
Louis, MO). Caspase-3 and cathepsin L were obtained from Biovision (San Francisco, CA). 
MMP-2 was purchased from Calbiochem (Gibbstown, NJ). 
2.3.2. Peptide elongation 
All peptides were synthesized on an automated solid phase peptide synthesizer (PS3, 
Protein Technologies, Tucson, AZ), employing the traditional N-α-Fmoc methodology on rink 
amide resin (0.1 mmol), as previously described [12]. Side-chain protections were Arg(Pbf), 
Asn(Trt), Lys(Boc), Ser(tBu), and Lys(ivDde). The coupling agent was 2-(1H-benzotriazole-1-
yl)-1,1,3,3,-tetramethylaminium hexafluorophosphate (HBTU), N-hydroxybenzotriazole (HOBt), 
and N,N-diisopropylethylamine (DIEPA) in N-methylpyrrolidinone (NMP) . 
2.3.3. Pegylation 
A mixture of Fmoc-NH-(PEG)27-COOH (308 mg, 0.2 mmol) and DIEPA (1 mL) 
dissolved in DMSO (4 mL) was added to the resin, followed by gentle shaking for 3 hr at room 
temperature. The Fmoc was removed by 20% (v/v) piperidine in DMF. Using the same protocol, 
Boc-NH-(PEG)27-COOH (285 mg, 0.2 mmol) was finally attached to the peptide N-terminus. 
2.3.4. Conjugation of NIR-664 to the peptide 
Prior to NIR-664 conjugation, the side-chain deprotecting group, ivDde (4,4-dimethyl-
2,6-dioxocyclohex-1-ylidene)-3-methylbutyl), was removed with 2% (v/v) hydrazine 
monohydrate in DMF (10 mL) [12]. The resin was washed three times with DMF. NIR-664-N-
succinimidyl ester (25 mg, 0.03 mmol) dissolved in DMSO (4 mL) was added to the resin (0.02 
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mmol). DIEPA (1 mL) was used as the catalyst. The reaction was allowed to react for 3 hr at 
room temperature.   
2.3.5. Peptide cleavage 
The resin was dried in methanol. A cleavage cocktail (2 mL) containing 
TFA/thioanisole/ethandithiol/anisole (90/5/3/2) was added to the resin for 3 hr at room 
temperature. The peptide was then precipitated in methyl-tert-butyl ether at 4°C and purified by 
reverse phase high performance liquid chromatography (rp-HPLC). The molecular weight of all 
peptides was confirmed by MALDI-TOF mass spectrometry (Tufts Medical School, Core 
Facility, Boston, MA). Peptide concentrations were determined by UV absorbance, according to 
the pre-determined extinction coefficient of NIR-664 (ε = 200,700 M-1cm-1 at 672 nm) in 80% 
(v/v) DMSO in water. 
2.3.6. NFP synthesis 
To synthesize NFP, either uPA-cleavable (PEG54-BK(NIR664)SGRSANA-kldlkldlkldl-
CONH2) or non-cleavable (PEG54-BK(NIR664)SGSARNA-kldlkldlkldl-CONH2) peptide-
conjugate (5 mg) was added to a mixture of 50% (v/v) acetonitrile in water (5 mL).  The solution 
was allowed to sit at room temperature overnight. The resulting NFP were then purified using 
Sephedex G-75 (GE Healthcare, Piscataway, NJ). The concentrations of all NFP were 
determined by UV absorbance, according to the extinction coefficient of NIR-664 (ε = 200,700 
M
-1
cm
-1
 at 672 nm) in 80% (v/v) DMSO in PBS. To make NFP of various lengths, the NFP 
solution was passed through a mini-extruder (Avanti polar lipids Ltd., Alabaster, AL) with 
polycarbonate membrane (Whatman, Florham Park, NJ) of different pore sizes (0.1 or 0.4 μm), 
which were then purified by size exclusion chromatography (GE Healthcare, Piscataway, NJ). 
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2.3.7. Transmission electron microscopy 
A solution of uPA (5 µg, 100 µL) was added to the NFP (4 µM, 100 µL) in a PBS buffer 
(10 mM, pH 7.4). The samples were allowed to incubate for 24 hr at room temperature. A small 
amount of NFP (20 µL) were then transferred onto the formvar/carbon-coated grids. Excess NFP 
were blotted off using a filter paper. The NFP were further stained with a 2% (v/v) uranyl 
formate solution [13]. The grids were allowed to dry and then examined under the TEM (JEOL 
100CX, Peabody, MA). For the inhibition study, the uPA was pre-incubated with amiloride (1 
mM) for 5 min prior to incubation with NFP. 
2.3.8. Fluorescence activation  
Different amounts of uPA (0, 6.25, 12.5, 25, and 50 µg, 100 µL) were added to the NIR-
NFP (4 µM, 100 µL) in the PBS buffer. Their fluorescence intensities were measured in a 
submicro cuvette (Starna cells, Atascadero, CA) by a fluorescence spectrometer (Cary eclipse, 
Varian, Palo Alto, CA) at different time points. All samples were excited at 665 nm, and their 
emissions were recorded at 684 nm. For the inhibition study, amiloride (1 mM) was added to the 
uPA prior addition to the NFP. For specificity studies, the NIR-NFP was incubated with other 
tumor-associated proteases including cathepsin L (12.5 µg/mL), prostate specific antigen (12.5 
µg/mL), caspase-3 (0.3 µg/mL), and MMP-2 (12.5 µg/mL).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
2.3.9. Cell lines 
Human cancer cell lines, SKBr-3, PANC-1, MCF-7, SKOV-3, MDA-MB-231, PC-3, and 
HT-1080 were purchased from ATCC. The non-cancerous cells (primary vascular smooth 
muscle cells and glial cells from rat) were supplied as generous gifts from Dr. Chengwen Sun 
(NDSU, Fargo, ND). HEK-293 cells were provided as a generous gift from Dr. Jagdish Singh 
(NDSU, Fargo, ND). All cell lines were cultured in their respective culture media as 
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recommended by ATCC. All culture media were supplemented with 10% FBS and antibiotics 
(100 U/mL penicillin G and 0.1 mg/mL streptomycin). All cells were cultured in incubators at 
37
o
C with 5% CO2 under humidified conditions. 
2.3.10. Western blot 
To determine the expression of uPA, all cells were grown to 80% confluency. The old 
media was discarded, and the remaining cells were rinsed twice with Hank’s balanced salt 
solution (HBSS). Cells were then incubated with serum-free McCoy’s 5A medium at 37oC with 
5% CO2 under humidified conditions. After 24 hr, the conditioned media was collected and then 
centrifuged at 1500 rpm for 5 min.  The supernatants were collected, centrifuged at 15,000 rpm, 
and concentrated with an Amicon Ultra-4 10k filter (Millipore, Billerica, MA). Micro-BCA 
assay (Pierce, Rockford, IL) was used to normalize the protein levels in all cell lines. The media 
(5 µL) was mixed with equal volumes of Laemmli buffer (BioRad, Hercules, CA) and then 
loaded onto 4-15% SDS-PAGE ready gel precast gels (BioRad, Hercules, CA). Electrophoresis 
was carried out at 80 V using Tris/glycine/SDS (25 mM Tris, 192 mM glycine and 0.1% (w/v) 
SDS, pH 8.3). Purified uPA (5 ng) was used as the positive control. After electrophoresis, the 
separated proteins were transferred to a polyvinylidene fluoride membrane (Hybond
TM
-P, 
Amersham, Piscataway, NJ). The membrane was then blocked with 5% (w/v) nonfat dry milk 
(BioRad, Hercules, CA) in 0.1% (v/v) Tween 20 in a Tris buffer saline (TBS) buffer, which was 
then incubated with primary mouse antibody against human urokinase (1:1000 dilution, 
American Diagnostica, Stamford, CT) in 0.1% (v/v) Tween 20-TBS, containing 1% (w/v) nonfat 
dry milk. After 4 hr, the membrane was washed with 0.1% (v/v) Tween 20-TBS (3 × 20 min) 
and allowed to incubate with secondary goat antimouse IgG (H+L) HRP conjugate (1:20,000 
dilution, ImmunoPure®, Pierce, Rockford, IL) for 1.5 hr.  The membrane was washed again with 
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0.1% (v/v) Tween 20-TBS (3 × 20 min), and uPA was detected with ECL
TM
 Western Blot 
Detection Reagents (Amersham, GE Healthcare Bio-Sciences, Piscataway, NJ) on Blue Ultra 
Autorad Film (BioExpress
® 
Kaysville, UT). 
2.3.11. Ex vivo activation of NIR-NFP 
The supernatants were prepared as described in western blot. Stock concentration of NIR-
NFP (1 µM) was prepared by diluting the NIR-NFP with PBS (10 mM, pH 7.4). The diluted 
NIR-NFP (60 µL) was added to the conditioned cell culture medium (60 µL). A similar 
procedure was followed for the scrambled substrate control NIR-NFP. The samples (100 µL) 
were transferred to a fluorescence cuvette, (Sub micro fluorometric cell, Starna cells, Atascadero, 
CA). Fluorescence emissions (at 684 nm) were recorded at 24 hr after incubation. Excitation 
wavelength was set at 665 nm. The enzyme activities secreted from individual cell lines were 
further quantified by interpolating the data from a standard curve. To generate a standard curve, 
different amounts of uPA (15-5000 µg/mL, 50 µL) (0.0625-10 µg/mL, 50 µL) of known 
activities, (where 1U = 2 µg), as determined by the supplier) were added to the NIR-NFPs (1 
µM, 50 µL). 
2.3.12. uPA activity assay 
The supernatants were prepared as described in the Western Blot section. The uPA 
activity was measured using the AssaySense Human uPA Chromogenic Activity Assay Kit 
(ASSAPRO, St. Charles, MO), according to the manufacturer's instructions. Briefly, all samples 
were pre-diluted in assay buffer, followed by addition to the uPA substrate.  The supernatant 
containing substrate solutions (100 µL) were then transferred to 96-well polystyrene microplate. 
The enzyme activities were monitored by absorbance at 405 nm at 4 hr after incubation. A 
standard curve of known uPA activities (between 0.015 and 2.5 U/mL) was generated at the time 
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the assay was performed. The activities of supernatants were interpolated from the standard 
curve.  Each reaction was performed in triplicate. 
2.4. Results and discussion 
2.4.1. The design of an NIR nanofiber precursor (NIR-NFP) 
To design an NIR-NFP for in vivo application, a previously reported NFP peptide 
construct was modified to comprise (1) a β-sheet peptide sequence (kldlkldlkldl, where k, l, and 
d are in D-configurations) for NFP assembly [201, 209] (2) a uPA substrate motif (SGRSANA) 
for enzyme cleavage [12, 13, 202, 210], (3) a polyethylene glycol (PEG54) to prevent inter-fibril 
aggregation, and 4) a conjugated NIR664 fluorophore as the optical reporter [211, 212] (Fig. 4).  
 
 
Fig. 4. Schematic presentation showing the design of an uPA-sensitive, near-infrared nanofiber 
precursor (NIR-NFP). The basic peptide construct of NIR-NFP is composed of a self-assembly 
peptide sequence (kldlkldlkldl), an uPA substrate motif (SGRSANA), a hydrophilic polyethylene 
glycol (PEG54), and a NIR reporter (NIR664). In an aqueous buffer, multiple NIR-NFP peptides 
(PEG54-BK(NIR664)SGRSANA-[kldl]3-NH2) spontaneously self-assembled to form an optically 
quenched NIR-NFP platform. Upon the addition of uPA, the enzyme digests the NIR-NFP, 
subsequently releasing the free NIR664-conjugated hydrophilic fragment (NH2-PEG54-
BK(NIR664)SGR-COOH), which results in fluorescence amplification. 
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In an aqueous buffer, multiple NFP constructs are expected to self-assemble to form a 2-
dimensional fiber via hydrophobic and electrostatic interactions [206, 213]. In the native state, 
the multiple NIR664 molecules attached to the NIR-NFP are orientated in a closed proximity; 
thus they become optical silent via static quenching. Upon activation with uPA, NIR664-
conjugated hydrophilic fragments (NH2-PEG54-BK(NIR664)SGR-COOH) can be released from 
the NIR-NFP, which in turn cause a significant increase in NIR fluorescence emission. The 
uniqueness of this NFP platform is that in simultaneous response to uPA digestion, the NIR-
NFPs will interact and transform into inter-fibril networks of micrometer size [214], which may 
potentially be used for protease-mediated drug delivery [215-220]. 
2.4.2. Synthesis and characterization of NIR-NFP  
The entire NIR-NFP (NH2-PEG54-BK(NIR664)SGRSANA-kldlkldlkldl-CONH2) and 
control NIR-NFP (PEG54-BK(NIR664)SGSARNA-kldlkldlkldl-CONH2) peptide constructs were 
synthesized in rink-amide resin (Fig. 5). We employed two homogeneous PEGs (Fmoc-NH-
(PEG)27-COOH and Boc-NH-(PEG)27-COOH) for pegylation, which was performed at the 
peptide N-termini by stepwise elongation. This method allowed NIR-NFP peptide to be 
synthesized as a homogenous moiety. NIR664, a cyanine dye, was introduced to the N-terminal 
lysine as the optical reporter. We found that NIR664, similar to some cyanine derivatives, 
displayed high chemical stability in TFA [221]. After cleavage, the NIR-NFP peptide was 
purified by rp-HPLC to > 90% purity (Fig. 6) and then lyophilized. MALDI-TOF MS analyses 
showed the expected molecular weight of the NIR-NFP peptide (Fig. 7, [M + H]
+
= 5487.77, 
calculated =  5486.45) (Fig. 7). 
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Fig. 5. NIR-NFP peptide synthesis. (A) The amino acid sequences of the NIR-NFP peptide 
construct and its control. (B) Synthetic scheme of the NIR-NFP peptide. 
 
 
Fig. 6. Analytical C-18 rp-HPLC chromatogram of the purified NIR-NFP peptide construct. The 
sample was eluted using a linear gradient (30 min) starting from 0 min with 20 % (v/v) of 
acetonitrile  in 0.1 % (v/v) TFA in water and ending at 30 min with 80 % (v/v) of  acetonitrile  in 
0.1 % (v/v) TFA in water. 
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Fig. 7. The MALDI-TOF spectrum of the NIR-NFP peptide. 
To synthesize the NIR-NFP, the peptide was dissolved in a mixture of acetonitrile and 
PBS.  Self-assembly was induced by solvent evaporation and it was allowed to be homogenized, 
as previously described [13]. The formation of NIR-NFP was confirmed by transmission electron 
microscopy (TEM). The as-prepared formulations were imaged as discrete fiber-like structures, 
spanning 1- 2 µM in length. The width of the NFP was extremely narrow (4 nm) depicting its 2-
dimensional structure. NIR-NFPs of various lengths (30 to 400 nm) could be fine-tuned by 
passing the samples through a mini-extruder, depending on the sizes of the pore filters employed.  
The fragmented fibers’ physical properties were similar to those of as-prepared fibers. 
Unlike previous studies, which showed that various self-assembling peptides were able to form 
fiber-like networks [201, 222], NIR-NFPs are individual fibers with no cross-linking (Fig. 8). 
This suggests that the incorporation of a hydrophilic PEG at the peptide N-termini can prevent 
the formation of 3-dimensional networks as a hydrogel. 
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Fig. 8. TEM images of a) 30 nm, b) 100 nm, and c) 400 nm NIR-NFPs. Images magnifications 
were 73k X. 
2.4.3. Fluorescence activation  
To study the fluorescence activation, 100 nm NIR-NFP (2 µM) was incubated with 
various amounts of uPA (µg/mL). The NIR-NFP concentration in all experiments was 
determined by UV absorbance (Fig. 9), according to our determined extinction coefficient 
(extinction coefficient = 200, 700 M
-1
cm
-1
 at 672 nm) of NIR-664 in 80% (v/v) DMSO in PBS. 
 
Fig. 9. The absorbance spectrum of NIR-NFP in 80% (v/v) DMSO in PBS.   
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Fluorescence emissions were measured at different time points (hr). We found that NIR-
NFP activation was uPA dependent. After 24 hr, up to 19.6-fold signal amplification was 
observed in samples incubated with a higher uPA level (Fig. 10A).   
To evaluate the specificity of NIR-NFP, we compared the activation kinetic level of NIR-
NFP with its control as well as in the presence of amiloride inhibitor. The control NIR-NFP 
consisted of a scrambled substrate sequence (SGSARNA) that is not recognized by uPA. With 
the addition of uPA, the fluorescence intensity of NIR-NFP increased with time, whereas the 
control did not show any changes (Fig. 10B). Fluorescence amplification was also significantly 
inhibited by amiloride inhibitor, confirming that NIR-NFP activation is specific to uPA. 
 
Fig. 10. Fluorescence activation of NIR-NFP.  (A) NIR-NFP (100 nm, 2 µM) was incubated with 
different amounts of uPA (μg/mL). Fluorescence intensities were recorded at different time 
points (hr). (B) Fluorescence intensity versus time scale (hr). NIR-NFP was incubated with (a) 
uPA only, (b) uPA plus amiloride inhibitor (1 mM), (c) the same amount of uPA, added to the 
control NIR-NFP, and (d) a PBS buffer only (10 mM, pH 7.4). (C) Comparison of NIR-NFP 
activations with different tumor-associated proteases. The NIR-NFP was incubated in either PBS 
alone or with proteases including uPA (12.5 μg/mL), cathepsin L (12.5 μg/mL), prostate specific 
antigen (12.5 μg/mL), caspase-3 (0.3 μg/mL), and MMP-2 (12.5 μg/mL). Fluorescence 
intensities were recorded at 24 hr after incubations. 
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Previously, we demonstrated that our employed substrate sequence “SGRSANA” for 
NIR-NFP is specific to uPA [223]. Here, we incubated the NIR-NFP with other tumor-associated 
proteases including MMP-2, cathepsin L, prostate specific antigen (PSA), and caspase-3.  As 
expected, these proteases did not activate the NIR-NFP (Fig. 10C), suggesting the employed 
substrate for NIR-NFP is specific to uPA. 
We next compared the fluorescence activation of NIR-NFP among various lengths (30, 
100 and 400 nm). Surprisingly, all NIR-NFPs showed similar fluorescence activation kinetics 
(Fig. 11). This may be explained by the fact that all NIR-NFPs had the same surface-area-to-
volume ratios, since they were structurally arranged in 2-dimension, thus uPA could assess to the 
substrate sites on the surfaces regardless of the length of the nanofibers. 
 
Fig. 11. Comparison of NIR-NFP of various lengths. Activation of NIR-NFP (2 μM). 
Fluorescence emissions (at 684 nm) were recorded at different time points (hr) after uPA (25 
µg/mL) addition in a PBS buffer (10 mM, pH 7.4). (Excitation wavelength = 665 nm) 
 
2.4.4. Structural modification 
To investigate the structural modification, 100 nm NIR-NFPs were subjected to TEM 
analysis. Previous studies of NFP demonstrated that the formation of inter-fibril networks upon 
protease activation was a stepwise process, involving the formation of intermediates such as 
elongates and laminates [214].  
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Here, the NIR-NFP was stable and showed no structural changes after 24 hr (Fig. 12). In 
contrast, the NIR-NFP transformed into inter-fibril networks after enzyme activation. The 
control NIR-NFP showed no structural changes with uPA. Our results were comparable to 
fluorescence activation studies. 
 
Fig. 12. Structural modification of NIR-NFP (100 nm, 2 µM) upon enzyme activation. TEM 
images of NIR-NFP. The images of NIR-NFP at (a) t = 0 hr and (b) t = 24 hr in PBS buffer (10 
mM, pH 7.4). uPA (25 µg/mL) was incubated with (c) NIR-NFP and (d) control NIR-NFP for 24 
hr. 
2.4.5. Ex vivo activation of NIR-NFP 
To investigate whether NIR-NFP can be used to detect cell-secreted uPA activity, we first 
collected the culture media from various cancer cell lines (SKBr-3, PANC-1, MCF-7, SKOV-3, 
MDA-MB-231, PC-3, and HT-1080). We then incubated the NIR-NFP in the media and 
monitored the fluorescence changes after 24 hr. We found significant increase in fluorescence 
signal recorded in cell lines expressing high levels of uPA such as HT-1080 and PC-3. On the 
contrary, no appreciable fluorescence changes in media of SKBR-3 (Fig. 13A) and some non-
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cancerous cells. The fluorescence changes were correlated with the protein expressions, as 
determined by western blot analysis. When control NIR-NFP was added to the HT-1080 media, 
there was no fluorescence change suggesting that the detection of uPA is specific. The amount of 
enzyme activities secreted from individual cell lines could be further quantified by interpolating 
the data from a standard curve (Fig.13B and Table 4). uPA activity can be counterbalanced by its 
natural inhibitor (uPAI) [224]. To confirm our results, we further employed a commercial 
activity assay kit. Unlike NIR-NFP, this assay determines uPA activities by using specific 
substrates that can be monitored by an increase in absorbance at 405 nm. 
 
Fig. 13.  Ex vivo activation of NIR-NFP. (A) The uPA activities in various cancer cell lines were 
determined by NIR-NFPs (100 nm, 0.5 µM) in conditioned culture media (100 µL). Control 
NIR-NFP was incubated in the HT-1080 media. All samples were recorded for fluorescence 
changes at 24 hr after incubation.  (B) A standard curve showing a plot of known amount of uPA 
activities (0.015-2.5 U in 100 µL, where 1 U = 2 µg of uPA) versus fluorescence activations by 
NIR-NFPs. (C) The activities of uPA in the culture media (100 µL) were confirmed by 
AssaySense Human uPA Chromogenic Activity Assay. (D) A linear plot showing NIR-NFP is 
comparable with the commercial activity assay for determine uPA activities in various cancer 
cell lines. 
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Table 4. Comparison between the NIR-NFPs and the uPA activity assay for determining uPA 
activities from different cancer cell lines.  
 
Cell  Line uPA Activity (U/mL) 
determined 
by NIR-NFP 
uPA Activity 
(U/mL) 
determined by 
activity assay 
SKBr-3 0 0 
MCF-7 0.26 ± 0.03 0.12 ± 0.01 
SKOV-3 0.71 ± 0.06 0.64 ± 0.02 
PANC-1 0.85 ± 0.08 0.78 ± 0.05 
MDA-MB-231 0.94 ± 0.09 0.85 ± 0.05 
PC-3 1.68 ± 0.14 1.65 ± 0.08 
HT-1080 1.72 ± 0.14 1.70± 0.08 
 
 
As expected, the uPA activities determined by NIR-NFPs were correlated with the 
activities determined by the commercial assay. There was no significant difference in uPA 
activities when NIR-NFP was incubated with non-cancerous cell-lines (Fig. 14). Overall, our 
data suggests that NIR-NFP is specific to uPA and can be used to quantify exogenous enzyme 
activity in ex vivo. 
 
Fig. 14. Fluorescence intensity of NIR-NFP in culture media of non-cancerous cells.  NIR-NFP 
(100 nm, 2 µM) was incubated with culture media obtained from, HEK293, primary vascular 
smooth muscle cells from rat (VSM), and primary glial cells from rat. Fluorescence intensities 
were recorded after 24 hr. There was no fluorescence increase in culture media obtained from 
non-cancerous cells.   
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Fig. 15. The expressions of uPA in supernatants of various cancer cell lines. The levels of uPA in 
SKBr-3, PANC-1, MCF-7, SKOV-3, MDA-MB-231, PC-3, and HT-1080 were determined by 
western blot. Lane 1 shows the human uPA as the positive control. The underlying bar graph 
shows the results of densitometric analysis of relative uPA levels from the western blot. The 
values indicated in the graph are means of three independent experiments. 
2.5. Conclusion 
 
Various fluorescent sensors such as polylysine copolymer [131], liposome [225], self-
assembly peptides matrices [12, 13], and polymeric nanoparticles [226] have been used for 
detecting tumor-associated proteases [127]. In the present study, we demonstrate an alternative 
approach, based on an NIR nanofiber precursor (NIR-NFP) system, for detecting uPA activity. 
Our optimized formulation (100 nm in size) was able to detect uPA in vitro with a 19.6-fold 
increase in NIR fluorescence signal; thus, it may be useful for in vivo imaging. The uniqueness 
of NIR-NFP is that it can transform into a micrometer-sized inter-fibril networking upon enzyme 
activation. We reasoned that upon uPA digestion, the activated NFP would no longer sustain its 
normal integrity, due to the loss of PEG-conjugated peptide fragments (PEG54-B-
K(NIR664)SGR-COOH). The resulting morphologies were similar to the self-assembly peptides 
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used for tissue engineering and drug delivery [206, 207, 227-229]. We also demonstrated that 
NFP was able to detect cell-secreted uPA in various cancer cell lines. 
A clinical cut-off value of uPA is usually between 3 to 10 ng per mg of protein, 
depending on the methods of analysis [230]. Our NIR-NFP was able to detect uPA within this 
range (as low as 3 ng) in 100 µL of sample. Experiments that involve testing the NIR-NFP for 
imaging uPA activity in xenograft model are currently underway. 
In conclusion, we have designed and characterized a peptide-based near infrared reporter 
for uPA. Our ultimate goal is to develop a patient-specific strategy for the diagnosis and 
treatment of cancer, based on the differential expression of tumor-associated proteolysis [231]. 
Overall, this approach may also apply to detecting other proteases.  
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CHAPTER 3. DESIGN AND SYNTHESIS OF A PEPTIDE-BASED NANOFIBER AS 
MULTIVALENT PLATFORM FOR INCREASING THE THERAPEUTIC EFFICACY 
OF HERCEPTIN 
3.1. Abstract 
A multivalent system is often employed to enhance the effectiveness of a targeted 
therapy. Here, we investigated the peptide nanofiber (NFP) as a multivalent platform to target the 
human epidermal growth factor receptor (HER-2), a receptor that is overexpressed in about 20% 
of breast cancer patients. The nanofiber (HER-NFP) was 100 x 4 nm in size and was assembled 
from multiple peptide units (mPEG-BK(FITC)SGASNRA-kldlkldlkldl-CONH2). HER-NFP was 
also attached with approximately ten Herceptin antibodies at the surface. Because of an increase 
in the multivalency, HER-NFP was able to truncate more cell surface HER-2 and thus showed an 
enhanced cytotoxicity towards HER-2 positive SKBr-3 human breast cancer when compared to 
the free Herceptin. Western blot and fluorescence microscopy studies confirmed that there was a 
significant down-regulation of the HER-2 level and also inhibition of the cell survival cell 
signaling pathways such as the phosphatidylinositol 3-kinase (PI3K) and the mitogen activated 
protein kinase (MAPK) pathway. Our data suggested that NFP can be a multivalent platform for 
immunotherapy, especially in combining with other chemotherapeutic agents in the future.  
3.2. Introduction 
3.2.1. Monoclonal antibody therapy 
Monoclonal antibody (mAbs)-based therapy has enormous potential for treating 
numerous human malignancies including cancer, heart disease, infection, and immune disorders 
[232-234]. Examples of FDA approved monoclonal antibodies used for the treatment of cancer 
are summarized in Table 5. 
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Table 5. List of monoclonal antibodies approved by FDA for different types of cancer.  
 
Product Generic name Target Type Approval Indications 
Rituxan
®
/Mabthera
®
 Rituximab CD20 
Chimeric 
IgG1 
1997 
B-cell 
lymphoma 
Herceptin
®
 Trastuzumab HER2/neu 
Humanized 
IgG1 
1998 
Breast 
cancer 
MabCampath
®
 Alemtuzumab CD52 
Humanized 
IgG1 
2001 
Chronic 
lymphatic 
leukemia 
Zevalin
®
 
90Y-
Ibritumomab 
CD20 
Murine 
IgG1-
radionuclide-
conjugate 
2002 
B-cell 
lymphoma 
Bexxar
®
 
131I-
Tositumomab 
CD20 
Murine 
IgG1-
radionuclide-
conjugate 
2003 
B-cell 
lymphoma 
Avastin
®
 Bevacizumab VEGF 
Humanized 
IgG1 
2004 
Colorectal 
cancer 
Erbitux
®
 Cetuximab EGFR 
Chimeric 
IgG1 
2004 
Colorectal 
cancer 
Vectibix
®
 Panitumumab EGFR 
Entirely 
human IgG2 
2006 
Colorectal 
cancer 
Arzerra
®
 Ofatumumab CD20 
Entirely 
human IgG1 
2009 
Chronic 
lymphatic 
leukemia 
Yervoy
®
 Ipilimumab CTLA-4 
Entirely 
human IgG1 
2011 Melanoma 
Adcetris
®
 
Brentuximab 
vedotin 
CD30 
Chimeric 
IgG1 
2011 
Non-
hodgkin 
lymphoma 
 
The main advantage of mAbs is their specificity and low toxicity as compared to small 
molecule chemotherapeutic drugs.  More than 25 mAbs have been approved by the US Food and 
Drug Administration (FDA), while there are 150 in different phases of clinical trials [235]. For 
the treatment of cancer, mAbs are most widely studied targeting ligands for diagnosis and 
therapy [236]. As carrier molecules, they have the ability to selectively localize in tumor tissue 
upon intravenous injection [237, 238]. Humanized and chimeric mAbs such as trastazumab, 
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bevacizumab, cetuximab, and panitumumab have been used in the treatment of breast, colorectal, 
lung, and gynecological cancers [239]. Despite these clear merits, the use of mAbs for 
monotherapy tends to be variable and non-curative due to their low potency [240, 241].   
Various strategies adopted to enhance the potency of antibodies, such as combination 
with chemotherapy [242], radiation therapy [243], thermal therapy [244], hormone therapy 
[245], and tyrosine kinase inhibitors [246]. The combination of antibodies with chemotherapy is 
one of the most common and widely accepted strategies for treatment of cancer, and provides 
advantage of simultaneous targeting of multiple cellular pathways occurs resulting in prevention 
of cancer spread [247, 248]. For example, adjuvant treatment of Herceptin with paclitaxel leads 
to significant improvement in overall survival rate of patients with HER-2 positive cancer [249]. 
Herceptin has also been used in combination with other chemotherapeutic drugs such as 
docetaxel [250], gemcitabine [251], capecitabine and CMF (cyclophosphamide, methotrexate, 
and fluorouracil) [252].  
Another strategy is to combine immunotherapy with hormone therapy [245, 253]. Level 
of hormonal receptors such as estrogen receptor and progesterone receptor are validated for 
administration of hormonal therapy [254-256]. Combination of Herceptin with hormonal therapy 
with drugs such as tamoxifen [253], and aromatase inhibitors [257] has been shown to improve 
outcome in patients with HER-2 overexpression.  
Antibodies have also been used in combination with radiotherapy [243]. Radiotherapy 
has been employed for several years in combination with chemotherapy after surgery and is 
widely accepted procedure for cancer treatment [258]. It mainly exerts its cytotoxic effect on 
cells by inducing DNA damage [259]. Herceptin when used along with radiotherapy in clinical 
trials demonstrated improved clinical benefit with no significant cardiotoxicity [260, 261] . 
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3.2.2. Strategies to increase therapeutic efficacy of monoclonal antibodies 
3.2.2.1. Multivalency 
Simultaneous interaction of multiple ligands to multiple receptors has been shown to lead 
to an increase in avidity in biological systems [262]. Naturally occurring antibodies are classified 
as IgM, IgG, IgE, IgD and IgA. The majority of mammalian IgG antibodies consist of two 
antigen binding sites (Fab) and one constant region (Fc). Binding to two antigens simultaneously 
contributes to enhanced functional avidity of IgG’s and longer residence time on cell surfaces 
[263]. Some antibodies may form higher valency complexes such as a dimer (IgA) or pentamer 
(IgM). Progress in genetic engineering has enabled easy manipulation of antibody structure to 
convert recombinant antibodies or their fragments into a multivalent format with the aims of 
improving the specific properties of antibodies [264]. The structure of the antibody can be 
modified, either via chemically [265] or recombinant technology [266] into a multivalent and/or 
a multispecific format to improve the stability [267], functional affinity [44], effector function 
[268], cytotoxicity [269], biodistribution, and pharmacokinetic profile [45].  
 For example, administration of tetravalent IgG was shown to significantly reduce the 
tumor growth rate upon homodimers as compared to the parental IgG [270]. The use of trivalent 
single-chain antibody fragment F(ab)3 complexes resulted in increased tumor uptake as 
compared to divalent F(ab)2 [271, 272]. Multimerization through engineering has also been 
applied for therapeutic antibodies, such as Herceptin. It was demonstrated that when anti-HER2 
741F8 (scFv) was constructed in a divalent format, there was a 3.5 to 4-fold increase in tumor 
accumulation as compared to monovalent scFv [273]. In another study, multimerization of anti-
HER-2 4D5 into di- and tetravalent minibodies led to significant improvement in functional 
affinity [45, 274].  
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3.2.2.2. Cell-mediated immunity  
Immune cells such as natural killer cells (NK), monocytes, and macrophages have the 
ability to serve as a natural defense mechanism against cancerous cells, through certain 
mediating processes such as antibody-dependent cellular cytotoxicity or complement-mediated 
lysis [275]. The reaction is triggered when the Fc region of the antibody binds the tumor cell, and 
the tumor cell is recognized by the Fcγ receptors on immune effector cells and results in 
phagocytosis and the release of granzymes leading to cell lysis [276]. Rituximab, monoclonal 
antibody used in the treatment of non-Hodgkin’s lymphoma acts by interacting with the Fc 
receptor of natural killer (NK) cells [277, 278]. Glycosylation or the incorporation of specific 
sugar residues on the antibody’s Fc region affects its binding with the immune cells. Degree of 
glycosylation can be controlled through protein engineering and may be employed for improving 
antibody’s stability, activity, pharmacokinetic profile and immunogenicity [279, 280]. In some 
cases, “defucylation” or the removal of core fucose residue has been performed [281]. For 
example, more than 50 fold improvement in antibody-dependent cellular cytotoxicity (ADCC) 
response was achieved through improved IgG binding to Fcγ receptor IIIa (FcγIIIa) [281-283] 
3.2.2.3. Attaching drug molecules to antibodies  
Antibody-drug conjugates (ADCs) are an emerging class of biotherapeutics with the 
potential to deliver highly potent drug specifically to the target cells [284-286]. ADCs combine 
the specificity of an antibody with the potency of small molecule anticancer drugs (Fig. 16). The 
resultant construct can efficiently localize in tumor cells and deliver its payload. Although the 
concept has been around for a long time, early ADCs had limited success in clinical trials due to 
limited selectivity, insufficient potency, and potential to cause immunogenicity [287, 288]. 
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Fig. 16. Diagrammatic representation of an antibody-drug conjugate. Antibody (A) is attached to 
drug molecules (B) with a covalent linker (C). 
 
  The approval of Mylotarg (gemtuzumab ozogamicin) for patients with acute myeloid 
leukemia (AML) in 2000, there has been a renewed interest in ADCs, particularly in cancer 
therapy. In 2011, another ADC, Adcetris (Brentuximab vedotin), was approved by US-FDA for 
treating lymphoma. Several companies have ADC products in various stages of clinical 
development. 
ADCs typically have three components: an antibody, small molecule drug, and a linker. 
Antibodies function as the targeting element in the construct and help in localizing the ADC into 
the tumor cells. Extensive research that has been done to improve the specificity of antibodies 
towards certain surface antigens and these advances can be leveraged in the rational design of the 
ADCs [289, 290]. Previously ADCs were mostly constructed from murine or chimeric antibodies 
which results in low binding affinity, faster clearance, and immunogenicity [291]. These 
concerns have been addressed lately by use of humanized or human antibodies with high target 
specificity and affinity. Small molecule drugs that have been used in ADCs are cytotoxic agents 
that target either tubulin or cellular DNA [292]. Examples of therapeutic agents conjugated to 
antibodies are summarized in Table 6.  
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Table 6. List of antibody-drug conjugates approved by FDA. 
Antibody-drug 
conjugate (ADC) 
Antigen Conjugated 
Drug 
Cancer Reference 
mAb-DM1                CD56 Maytansine Lung  [293] 
Mylotarg CD33 Ozogamicin Leukemia  [294] 
BR96-doxorubicin LeY Doxorubicin Breast   [295] 
mAb-MMAF CD70 Auristatin Renal  [296] 
mAb-MMAE CD30 Auristatin Hodgkin   [297] 
These molecules are generally very potent but lack selectivity towards target cells. 
Therefore, when administered systemically, they exhibit toxicity towards normal tissues even at 
very low doses which severely limits their application as anticancer agents [298, 299]. 
Conjugation with a targeting element such as an antibody drastically reduces the dose required 
and can provide efficient tumor targeting.The attachment of antibody  require a linker that 
conjugate the drug with the monoclonal antibody covalently without affecting their individual 
function [300, 301]. Linkers are a key component to a successful ADC as they must be designed 
to be stable during systemic circulation but degrade in the cellular environment to release the 
cytotoxic agent [302-305]. Therefore, routing of drug into the desired component in the cell can 
be adjusted by choosing the appropriate linker. The most commonly used linkers include 
hydrazone linkers that degrade in the acidic microenvironment of the lysosomes and disulfide-
based linkers that are cleaved in the reductive environment of the cytosol [306-308]. 
For example, hydrazone linkers are designed so that they can be to be pH-sensitive and 
release drug in slightly acidic compartments of the cell, such as lysosomes [309]. Lysosomal 
drug release can also be achieved by using peptide linkers that can be cleaved by lysosomal 
proteases such as cathepsins [310]. Peptide linkers such as the valine-citruline linker are also 
commonly used, especially for auristatin drugs [311]. Recently polyethylene-based linkers (PEG) 
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have been explored to improve solubility and extend circulation half-life of the conjugate [312, 
313]. They have been attached not only to antibodies but also several nanoparticles. 
3.2.3. HER-2 receptor signaling 
The EGFR family of transmembrane receptor comprises of HER-1, HER-2, HER-3 and 
HER-4 [314, 315]. They are 185 kDa and comprise of three specific regions extracellular domain 
(ECD), membrane spanning region, and cytoplasmic tyrosine kinase domain. These receptors are 
crucial for normal growth and functioning of cells, and can be activated upon the binding to 
various EGFR proteins and growth factors [316-318].  Activation of the receptor can lead to 
either cross-linking of same receptor to the form homodimer or heterodimer between two EGFR 
receptors, which in turn results in phosphorylation of tyrosine residues in the intracellular 
domains of the receptor and triggering activation of pathways such as phosphoinositol (PI3K), 
mitogen activated protein kinase (MAPK) and phospholipase (PLC) [319, 320]. Upon 
phosphorylation, the downstream signaling events lead to the promotion of cell growth and 
inhibition of apoptosis. Among the HER family, HER-2 has emerged as an attractive therapeutic 
target for breast cancer. Under normal conditions, HER-2 levels are low on surface of epithelial 
cells; however, gene amplification up to 20-30% is observed in breast cancer [46-48]. 
Overexpression of HER-2 has also been noted in many other human cancers such as, ovarian 
[321], lung [322], and gastric cancer [323]. In addition, clinical data has shown that enhanced 
HER-2 levels are associated with metastasis potential and overall poor patient prognosis [72].  
3.2.4. Herceptin 
Herceptin is a humanized monoclonal antibody directed against the ECD of HER-2 and 
was the first monoclonal antibody approved by FDA in 1998 for the treatment of patients with 
metastatic breast cancer (MBC) [324]. Clinical trials of Herceptin have been conducted in both 
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mono-therapy and in combination with chemotherapy [325-330]. Initial approval of Herceptin 
was based on randomized phase III studies combining Herceptin with chemotherapeutic agents 
such as paclitaxel and anthracycline in previously untreated patients and showed significant 
improvement in overall survival rate, progression free survival,,and objective response rate over 
treatment with chemotherapy alone. As single therapy agent in MBC, Herceptin resulted in 
overall response rate of 19-26% [327]. Subsequent clinical trials have shown that Herceptin 
could be combined with other therapeutic agents such as docetaxel [328], gemcitabine [329] and 
vinorelbine [330]. Herceptin has also been used to improve targeting and reduce systemic 
toxicity by conjugating to a variety of drugs or drug loaded nanocarrier systems such as quantum 
dots, liposomes, nanoparticles, and iron oxide nanoparticles [331-333].  
3.2.5. Herceptin: Mechanisms of action 
3.2.5.1. Disruption of downstream MAPK and PI3K/Akt signaling pathways 
The two main pathways downstream of HER-2, phosphoinositol-3 kinase (PI3K) and 
mitogen activated protein kinase (MAPK) pathways are crucial for cell growth, proliferation, and 
inhibition of apoptosis [334, 335]. Interference in the i.e. MAPK and PI3K is most widely 
accepted mechanism that is crucial for the inhibitory action of Herceptin [336]. It is believed that 
the binding of Herceptin to the HER2 receptor prevents the dimerization of HER-2 and 
subsequent phosphorylation of downstream signaling substrates such as Akt [337] (Fig. 17). In a 
preclinical study, the binding of Hereptin to HER-2 overexpressing breast cancer cells lead to 
upregulation of tumor suppressor PTEN (phosphatase and tensin homolog) and downregulation 
of PI3K activity [338]. There is also evidence to suggest that the binding of Herceptin to HER-2 
can result in inhibition of tyrosine kinase Src and, thus, increase PTEN level, which is a tumor 
suppressor [338]. 
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Fig. 17. Schematic scheme showing the various mechanism of action of Herceptin. 
3.2.5.2. Inhibition of angiogenesis 
In cancer, there is often high vascularization in tumors since they require constant supply 
of nutrients for their growths and proliferations [339, 340]. It is reported that HER-2 positive 
tumors overexpress vascular epidermal growth factor receptor (VEGF). In a preclinical study 
involving HER-2 overxpressing cells, Herceptin treatment was shown to suppress angiogenesis 
and vascularization due to downregulation of VEGF [341]. Similar observation was observed in 
mice when Herceptin treatment led to normalization of blood vessels [342]. When Herceptin 
treatment was combined with Paclitaxel, synergistic results were obtained [343]. This was 
believed to be due to the fact that paclitaxel is more efficient in delivery to tumor due to 
normalization of tumor vasculature [343]. 
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3.2.5.3. Induction of antibody-dependent cell cytotoxicity  
Antibody-dependent cellular cytotoxicity (ADCC) is one of the major mechanisms of 
action of Herceptin. Immune effector cells, such as natural killer cells have Fcγ receptor which 
can be detected by Fc portion of Herceptin [344]. Binding of Herceptin to HER-2 receptor 
attracts immune cells to tumor sites and results in lysis of HER-2 positive target cells (Fig. 17). 
This was evidenced by study in which antitumor activity of Herceptin was markedly reduced in 
mice bearing defective Fcγ receptors [345]. 
3.2.5.4. HER-2 degradation  
Inhibitory action of Herceptin may be due to internalization and degradation of HER-2 
receptor. Herceptin first binds to the HER-2 receptor, and the antibody bound receptor undergoes 
sorting in degradation compartments in the cell, a process known as “ubiquitination” through the 
activation of enzyme ubiquitin ligase cCbl [346]. A study previously demonstrated that 
Herceptin can enhance the activity of ubiquitin ligase c-Cbl, which further promotes HER-2 
degradation [347]. 
3.2.5.5. Inhibition of ErbB2 extracellular domain proteolysis  
Studies have shown that 185 kDa HER-2 receptor can undergo proteolytic cleavage to 
form a 115 kDa HER-2 fragment. Interestingly, patients with high level of 115 kDa p95HER2 
fragments in their serum are associated with more aggressive tumors [348]. When treated with 
Herceptin, these patients exhibited dose-dependent decrease in HER-2 ECD level in serum and 
improved tumor response rates and PFS [348]. Previous study indicated that Herceptin prevents 
proteolytic cleavage through steric hindrance, which could be possible mode of action for 
Herceptin [349]. 
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3.2.6. Limitations associated with Herceptin therapy 
Herceptin has been a remarkable example for successful monoclonal antibody therapy; 
however, despite the success of Herceptin, there are limitations due to potential development of 
side-effects [350]. It is found that about 4% of the patients treated with Herceptin developed 
congestive heart disease (CHF) [351, 352]. Moreover, the incidence of cardiotoxicity increased 
upto 28% when patients were co-administered chemotherapeutic agents such as anthracyclines 
[353]. 
Another cause of modest duration of response is development of primary or secondary 
resistance. It has been observed that about 70% of patients who initially responded to therapy 
experienced metastatic progression of the disease within one year [354]. Very little information 
on development of primary and secondary resistance, however multiple potential mechanisms of 
resistance to Herceptin were proposed [355, 356]. Understanding the mechanisms behind 
Herceptin resistance is crucial for development of novel anti-HER-2 strategies for breast cancer. 
3.2.7. Strategies to encounter Herceptin resistance 
There are various strategies that are used to overcome resistance of Herceptin towards 
HER-2 positive cells (Table 7). Herceptin has been administered along with other antibodies, 
such as Pertuzumab. Pertuzumab acts by preventing heterodimerization of HER-2 with other 
members of HER receptor family [357]. Phase III clinical trials are being performed to evaluate 
the outcome of co-administering Herceptin and Pertuzumab in patients with HER-2 
overexpressing metastatic breast cancer [358]. Herceptin has also been combined with agents 
targeting other pathway such as inhibitors of mTOR signaling and PI3K-AKT pathway such as 
RAD001 (Novartis, NY) [359] and CCI-779 (Wyeth-Ayerst; Madison, NJ) [360]. In another 
strategy, Herceptin has been fused with toxins, such as DM1 [361].  
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Table 7. Examples of various drug combinations to overcome resistance of Herceptin. 
Drug/antibody 
 
Pharmaceutical 
company 
Phase of 
study 
 
Combination 
with 
Herceptin 
Reference 
mTOR inhibitors     
Everolimus 
(RAD001) 
Novartis 
 
Phase II 
 
Yes 
 
[359] 
PI3K inhibitors     
BKM120 Novartis 
 
   
Angiogenesis 
inhibitors 
    
Bevacizumab Genentech Phase II 
 
Yes [362] 
Dimerisation 
inhibitor 
    
Pertuzumab GlaxoSmithKline   [358] 
Pazopanib GlaxoSmithKline Phase III No [363] 
Tyrosine Kinase 
Inhibitors 
    
Neratinib 
(HK-272) 
Pfizer Phase II Yes [364] 
Afatinib 
(BIBW-2992)  
Boehringer 
Ingelheim 
  [365] 
Antibody-Drug 
Conjugate 
    
Herceptin-DM1 Genentech Phase II ---- [361] 
 
Lapatinib belongs to the family of inhibitors of tyrosine kinase activity of receptors such 
as EGFR and HER-2 and has proven to be successful in inhibiting the downstream signaling 
through these receptors in preclinical studies [366]. The synergistic effect of Herceptin and 
lapatinib has been evaluated in advanced stage of breast cancer [367]. 
3.2.8. Nanomaterial as tumoral delivery cargos 
Over the last several decades, numerous nanoparticles have been developed for both 
imaging and therapeutic application [368-370]. Designing material at nanometer scale provides 
the flexibility of modifying some of their important fundamental properties for enhancing drug 
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deliver, such as solubility, biodistribution, pharmacokinetic properties, which can be translated 
into enormous advantages in clinical situations by causing reduction in dosage, better 
pharmaceutical effects, minimization of side-effects, and enhanced drug stability. In the field of 
imaging, nano-scaling of materials has been exploited to achieve enhanced optical, magnetic and 
radioactive signals [371].  
Nanocarriers have been investigated for a broad range of diagnostic and therapeutic 
applications. Owing to their size, nanocarriers provide unique advantages when compared to 
larger systems, such as improved biodistribution, pharmacokinetics, and reduction of side-
effects. [372-375]. Nanocarriers have been of particular interest in tumor targeting because they 
are flexible in meeting the needs of pathological conditions of cancer. Traditionally, two 
strategies that have been employed for delivering nanocarriers to the tumors, passive and active 
targeting [376]. Passive targeting utilizes an important characteristic of tumor anatomy. Growing 
tumors have leaky vasculature with pores in the range of 100-400 nm that allow extravasation of 
particles smaller than 100 nm. The ability of particles < 100 nm to pass through leaky 
vasculature of tumor presents an excellent opportunity for passive targeting of drugs [377, 378]. 
Upon reaching the tumor tissue, nanocarriers release the drug. Clearance of nanocarriers from 
the tumor is slow due to impaired lymphatic drainage. This phenomenon, known as enhanced 
permeability and retention (EPR), results in preferential accumulation of nanocarriers in the 
tumor tissue [379]. However, a majority of nanoparticles tend to undergo non-specific uptake by 
reticuloenothelial system (RES) such as monocytes and macrophages and therefore have less 
circulation time. Therefore, nanocarriers have been to have longer circulation time and escape 
recognition by reticuloendothelial system (RES). Polyethylene glycol is routinely used for this 
application as it can reduce protein interaction on the surface due to its hydrophilicity [380].  
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Although passive targeting is attractive, it does have some limitations such as dependence 
on tumor pore size and elevated interstitial pressure which make this approach inefficient in 
certain cases [381, 382]. Active targeting involves conjugation of a drug, biologics, or a 
diagnostic agent on the surface of a nanocarrier [236, 376, 383]. Moieties that can be delivered 
through conjugation include peptides [384], proteins [385], polysaccharides [386], DNA [387], 
and siRNA [388]. Nanocarriers provide large surface area to volume ratios which facilitate 
greater binding efficiency and penetrability compared to larger systems. Active targeting as 
generally been more successful compared to passive targeting since the assembly is internalized 
quickly inside the cells after interaction with surface proteins [389]. Antibodies have been used 
most commonly as a targeting agent. Conjugation of nanoparticles with antibodies offers the 
unique advantage of combining specificity of antibodies with the size advantage of 
nanoparticles. A number of studies have explored targeting efficiency of nanoparticles 
conjugated with antibodies [390-393]. Results suggest that active targeting may not necessarily 
be superior to passive targeting in terms of tumor localization but would lead to more efficient 
cellular internalization [376]. Whereas in case of passive targeting, the assembly may not be 
internalized quickly leading to eventual clearance from the tissue. Active targeting is also more 
susceptible to clearance by the RES system since the targeting molecule is exposed on the 
surface [394].  To further enhance the capability of entrapment, efforts are directed towards 
creating functionalizing nanoparticles surfaces with targeting molecules, such as antibodies, 
peptides, small molecules and oligonucleotides. The combination of small size of nanoparticle 
and the specific recognition properties of the targeting moiety allows excellent discrimination 
between hypervasculature and established blood vessels and accumulation at desired locations 
[395, 396].  
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3.2.9. Self-assembly peptide based material 
Materials derived from self-assembly peptides are generating interest in a variety of 
biomedical applications such as tissue engineering, drug delivery and diagnostic imaging [397-
399].  The first self-assembly peptide nanofiber sequence EAK16, “zuotin” was discovered from 
yeast. It was a 16 amino acid residue and contained DNA binding properties. After its initial 
discovery, there have been numerous reports on use of peptide nanofibers in a variety of 
biological and biomedical applications Their main advantage is biocompatibility, flexibility of 
design and structure, and low immunogenicity [400, 401].  The design principle of most peptide 
nanofibers is the placement of alternating hydrophobic and electrostatic amino acids. Individual 
beta sheet peptide in nanofiber is about 8-16 amino acids long.  Under aqueous conditions, there 
is formation of stable beta sheets which is mediated by electrostatic interaction, hydrophobic 
interaction, and Van der Waals interaction [402, 403]. The formation of these peptide assemblies 
may be enhanced upon exposure to physiological salt and different pH environments [404, 405]. 
Once formed, beta sheet peptides are stable across wide range of temperature, pH, and presence 
of denaturating agents such as urea and guanidine hydrochloride [207]. Depending on the nature 
of self-assembly, the fibers may be of varying diameters (7-20 nm), but are usually composed of 
99% water. Another interesting property of peptide nanofibers is that they mimic extracellular 
matrix, and therefore have been used to improve cell adhesiveness, induce differentiation and 
proliferation in three-dimensional tissue engineering and regenerative medicine. 
3.2.10. Nanofibers as a carrier for drugs 
Recently, there are increasing recognitions of using peptide-based nanofiber (PF) in 
tissue engineering [207], diagnostic imaging [11, 13], and drug delivery [208, 222]. The main 
advantage of using peptide nanofiber is that they are composed from biocompatible amino acids. 
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The uniqueness of PF is its flexibility to subject to modification. Since nanofibers are composed 
of amino acids, the side groups of the amino acids can be used to conjugate functional moities, 
such as small molecules, proteins and, fluorescent dyes. For example, functional motifs such as 
collagen derivatives and platelet derived growth factor receptor (PDGF) have been integrated 
into PFs to retain the degree of cellular entrapment or recruitment in tissue engineering [406, 
407], or peptide substrates have been inserted into PF for imaging tumor-associated protease 
activity [11, 13, 214]. Furthermore, various therapeutic agents including small drug molecules 
[408-410], peptide [411, 412], proteins [413, 414] have also been incorporated into the PFs to 
enhance the delivery to the target sites. The exploration of peptide nanofiber as template for 
multivalent presentation of molecules is especially attractive for the following reasons: (1) 
peptide nanofibers present certain functional groups such as –NH2 and –COOH for conjugation 
of optical fluorophores or protein molecules (2) High loading capacity, which is not in the case 
of high molecular weight, which is not possible in the case of polymers [415]. (3) Flexibility of 
design and structure and scope for multifunctional platform and imaging application, and (4) 
Ease of synthesis and biocompatibility. Multiple antibodies can be covalently attached to the 
surface of a nanomaterial such as gold nanoparticles [416], quantum dots [417], magnetic 
nanoparticles [418], liposomes [419], polymeric nanoparticles [420] and dendrimers [421]. For 
example, antibodies against intercellular adhesion molecule 1 (anti-ICAM1) have been attached 
to a polymeric nanoparticle to improve the pulmonary targeting [420, 422].  
In other study, antibodies against epidermal growth factor receptor (anti-EGFR) were 
conjugated to a gold nanoparticle to enhance its tumor accumulation [423]. Examples of self-
assembly peptide based nanofibers used in drug delivery application have been listed in Table 8. 
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Table 8. Self-assembly peptide-based material used in drug delivery applications. 
Peptide Drug/Protein Application Reference 
Heparin-binding peptide 
amphiphile 
VEGF/FGF-2 Islet 
transplantatio
n 
[424] 
AcN-
RARADADARARADADA-
CNH2 
PDGF-BB Myocardial 
protection 
[425] 
Ac-(R-A-D-A)4-CONH2 Insulin Diabetes [426] 
RADA16-II IGF-1 Myocardial 
infarction 
[427] 
Ac-FEFQFNFK-NH2 Ellipticine Cancer [428] 
RADA-16 Paclitaxel Cancer [429] 
Palmitoyl-A4G3E3 Camptothecin Cancer [430] 
Dex-peptide amphiphile Dexamethasone Inflammation [431] 
GTAGLIGQRGDS Cisplatin Cancer [216] 
Taxol-SA-GSSG Taxol Solid Tumors [432] 
Peptide amphiphile BMP-2 Tissue 
engineering 
scaffold 
[433] 
RADA16-I -- Wound 
dressing 
[434] 
RADA16-I EGF Wound 
healing 
[435] 
 
3.2.11. Unique features of peptide nanofibers for drug delivery applications 
 The size of NFP is small enough to permeate through small capillaries of tumor. A large 
portion of the NFP consists of hydrophilic polyethylene glycol (PEG). Several PEG protein 
conjugates have been approved by FDA such as PEG-Asys
®
, PEG-intron
TM
, Oscaspar
®
, 
Neulasta
TM 
as demonstrated in previous studies [436]. Similar to previous studies, we expect that 
PEG conjugation to HER-NFP will reduce its immunogenicity, improve its stability, and prolong 
its half-life by preventing renal elimination and avoidance of receptor-mediated protein uptake 
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by reticuloendothelial system (RES) [437]. 3) A large fraction of the peptide is constructed with 
D-amino acids. For clinical applications, constructing nanomaterial with D-peptides is 
advantageous as they are highly resistant to proteolytic degradation and relatively 
immunologically inert in comparison to their natural counterparts [438]. Upon reaching the 
target, the slow degradation of D-peptides could be used for controlled drug delivery 
applications. 
3.3. Material and methods 
3.3.1. Materials 
All solvents were purchased from Fisher Scientific (Fair Lawn, NJ). The amino acids 
were purchased from Novabiochem (San Diego, CA). Methoxyl polyethyleneglycol N-
hydroxysuccinimide ester (mPEG NHS ester, average MW of 2 kDa) was purchased from 
Jenkem Technology USA Inc. (Allen, TX). Anisole, ethandithiol, fluorescein isothiocyanate 
(FITC), sodium borohydride, sodium periodate, thioanisole were obtained from Sigma (St. 
Louis, MO). Herceptin was purchased from Genentech (South San Francisco, CA). Cy5.5 
hydroxysuccinimide ester was purchased from GE Healthcare (Piscataway, NJ). And finally, the 
antibody-conjugated gold nanoparticles were purchased from Rockland Immunochemicals Inc, 
(Gilbertsville, PA).  
3.3.2. Synthesis and characterization of NFP  
The NFP peptide construct (mPEG2000-BK(FITC)SGASNRA-kldlkldlkldl-CONH2) was 
synthesized on an automatic peptide synthesizer using the traditional Fmoc methodology as 
previously described [13, 214]. The NFP was assembled by dissolving the peptide constructs (10 
mg) in 50% (v/v) acetonitrile in water (5 mL) and was further stirred overnight to evaporate the 
organic solvent. The resulting NFP was then homogenized by a mini-extruder (Avanti polar 
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lipids Ltd., Alabaster, AL) using the polycarbonate membrane (Whatman, Florham Park, NJ) of 
0.1 µm pore size, which was then purified by size exclusion chromatography using Sephadex G-
75 (Sigma, St. Louis, MO) in PBS buffer. The concentration of NFP was determined according 
to the extinction coefficient of FITC in 95% (v/v) methanol (65,000 M
-1
cm
-1 
at 500 nm), unless 
otherwise stated. 
3.3.3. TNBSA assay 
A commercial spectrophotometric 2,4,6-trinitrobenzenesulfonic acid (TNBSA) assay kit 
(Pierce, Rockford, IL) was employed to determine the loading efficiency of NFP. Briefly, a 
known concentration of NFP (30 µM, 250 µL), in Na2CO3 solution (10 mM, 250 µL), was mixed 
with TNBSA reagent (250 µL) and 10% (w/v) sodium dodecyl sulfate solution (SDS) in water 
(250 µL). This solution mixture was then transferred to 96-well polystyrene plate and further 
allowed to incubate for 3 hr at 37°C.  Following incubation, the absorbance of the TNBSA-NFP 
adduct was read at 335 nm. Under the same conditions, a standard curve was generated based on 
known concentrations of L-cysteine solution (0, 15, 30, 60, and 120 µM) to calculate the 
percentage of free -NH2 groups.  
3.3.4. Conjugation of Cy5.5 to the NFP  
The NFP solution (30 µM), in PBS buffer (10 mM, pH 7.4, 250 µL) was reacted with 
Cy5.5 NHS ester (250 ng), and allowed to incubate at room temperature in the dark for 2 hr. 
Following incubation, the unreacted fluorophores were removed by size exclusion 
chromatography using Sephadex G-75 column (GE Healthcare Biosciences, Piscataway, NJ). 
The fluorophore concentration was determined by absorbance according to molar extinction 
coefficient of Cy5.5 (250,000 M
-1
cm
-1 
at 675 nm) in PBS buffer. The total NFP peptide 
concentration was calculated according to molar extinction coefficient of FITC (65,000 M
-1 
cm
-1 
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at 500 nm) in 95% (v/v) methanol. To calculate the percentage of -NH2 groups reacted with 
Cy5.5 N-hydroxysuccinimide, the total concentration of Cy5.5 was divided by the concentration 
of NFP peptide multiplied by 3 (the number of -NH2 groups per peptide) and then times 100 %. 
3.3.5. Synthesis of Herceptin conjugated nanofiber (HER-NFP) 
A series of HER-NFP conjugates (100 nm) of different loading density of Herceptin (2, 4, 
10 and 20 Herceptin per NFP) were prepared. Briefly, sodium periodate (180 mM, 50 µL) was 
added to varying concentrations of Herceptin (1 mg/mL, 2 mg/mL, 10 mg/mL and 20 mg/mL) in 
a fixed volume (50 µL) of sodium acetate buffer  (10 mM, pH 4) to obtain Herceptin-to-NFP 
ratio of 2:1, 4:1, 10:1 and 20:1 respectively. The mixtures were then kept at room temperature 
for 1 hr and further dialyzed against NaHCO3 solution (0.1 N) employing a membrane with 14 
kDa molecular weight cut-off (MWCO) (Spectrum Laboratories Inc., Rancho Dominguez, CA) 
for 3 hr. NFP (20 µM, 250 µL) were then added to the solution mixture and incubated overnight. 
The resulting conjugates were reduced by adding sodium borohydride (1 mg) to the reaction 
mixture. The unconjugated antibody was then removed by dialysis using membrane with a 300 
kDa MWCO in PBS buffer (10 mM, pH 7.4). The purified conjugates (HER-NFP) were 
homogenized and further purified by gel filtration.  
3.3.6. Determination of molar ratio of Herceptin and NFP in HER-NFP 
The number of peptides in each HER-NFP could be calculated from thickness of  each  
beta-sheet strand (~0.47 nm) [439]. At the same time, the concentration of Herceptin in each 
HER-NFP was determined by BCA assay (Pierce, Rockford, IL). To calculate number of 
Herceptin conjugated to nanofiber, the concentration of Herceptin was divided by the 
concentration of NFP in the stock solution. 
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3.3.7. Confirmation of the covalent attachment of Herceptin to NFP by electrophoresis 
Herceptin (300 nM), HER-NFP (300/30 nM), and a mixture of Herceptin (300 nM) and 
NFP (30 nM) were loaded in sodium dodecyl sulfate-polyacrylamide (SDS-PAGE) gel. The 
concentrations indicated were normalized for Herceptin.  As negative control, NFP alone (6 µM) 
was also used for analysis. Electrophoreses was performed for 2 hr at 80V on a Mini-Protean 3 
cell (Bio-Rad Laboratories, Hercules, CA). Following electrophoresis, the samples were stained 
using Coommassie Blue staining solution (Bio-Rad Laboratories, Hercules, CA). Images of the 
gel were taken with FluorChem 5500 imaging system (Alpha Innotech, Santa Clara, CA).  
3.3.8. Transmission electron microscopy staining 
HER-NFP (2 µM) suspended in PBS buffer (10 µL) was incubated with secondary anti-
human IgG-conjugated gold nanoparticles (10 µL) for 1 min at room temperature. HER-NFP 
was incubated with anti-mouse IgG-conjugated gold nanoparticles as the control sample. The 
samples were then added to 200 mesh form var-coated copper grids and further stained 
negatively with uranyl formate solution in water (2% w/v). Excess solution was removed by 
adsorbing on filter paper, followed by three washes, and air dried. The grids were then examined 
under the TEM (JEOL 100CX, Peabody, MA). 
3.3.9. Cell culture 
Human breast cancer cell lines SKBr-3, MCF-7, and MDA-MB-231 cells expressing 
high, moderate, and low level of HER-2, respectively, were purchased from ATCC (Manassas, 
VA). SKBr-3 cells were cultured in McCoy’s medium. MCF-7 cells were cultured in Eagle’s 
Minimum Essential Medium (EMEM) media supplemented with insulin (10 µg/mL), also 
purchased from ATCC (Manassas, VA). MDA-MB-231 cells were grown in Dulbecco's 
Modified Eagle's medium (DMEM). All culture media were supplemented with 10% v/v fetal 
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bovine serum (FBS) (Mediatech Inc., Manassas, VA). All culture media was supplemented with 
antibiotics such as penicillin G (100 U/mL) and streptomycin (100 µg/mL), which were obtained 
from ATCC (Manassas, VA). All cells were cultured in incubators at 37
o
C with 5% CO2 under 
humidified conditions. 
3.3.10. Cellular uptake of HER-NFP with varying density of Herceptin 
HER-NFP (100 nm) preparations with varying density of Herceptin-to-NFP (H/N) ratio 
(2:1, 4:1, 10:1 and 20:1) were normalized to fixed concentration of Herceptin (200 nM). The 
HER-NFP’s were then conjugated to the same amount of Cy5.5 NHS ester (250 ng) according to 
manufacturer’s recommendation (GE Healthcare, Piscataway, NJ). The Cy5.5-conjugated HER-
NFP (Cy5.5-HER-NFP) preparations were incubated with SkBr-3 cells for 12 hr. After 
incubation, cells were lysed in cell lysis buffer (110 µL) (Cell Signaling Technology, Danvers, 
MA), centrifuged at 12,000 rmp and fluorescence intensity in supernatants (100 µL) was 
recorded in a sub-microcuvette (StarnaCells, Atascadero, CA, USA) by a ﬂuorescence 
spectrometer (Cary Eclipse, Varian, Palo Alto, CA, USA).  At the same time, a standard curve of 
known concentration of Cy5.5-Herceptin (0, 10, 20, 40, 80, 160 and 450 nM) was plotted. 
Amount of Herceptin internalized was interpolated from standard curve. All samples were 
excited at 665 nm, and their emissions were recorded at 684 nm. To investigate kinetics of 
internalization, either Cy5.5-HER-NFP (H/N 10:1) or Cy5.5-Herceptin were incubated with 
SKBr-3 cells for 12 hr. The concentration of Herceptin was same (300 nM) in both these 
samples. The amount of Herceptin internalized at various time points (2, 4, 8, 12 and 24 hr) was 
determined using standard curve of Cy5.5-Herceptin, as described above. To investigate size-
dependency on cellular uptake, Cy5.5-HER-NFP (200/20 nM) was passed through mini-extruder 
(Avanti polar lipids Ltd., Alabaster, AL) fitted with polycarbonate membranes (Whatman, 
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Florham Park, NJ) of different pore size (50 nm, 100 nm and 400 nm). Uncut Cy5.5-HER-NFP, 
Cy5.5-Herceptin and Cy5.5-IgG-NFP (100 nm) were treated as controls. After 12 hr of 
incubation, the amount of Herceptin/IgG internalized in cells for all samples was analyzed as 
mentioned above.  
3.3.11. Cellular imaging 
SkBr-3 cells (10,000 cells/ well) were seeded in a 4-chamber slide (Thermo Fisher 
Scientific, Rochester, NY) in McCoy’s culture media and allowed to attach for 24 hr. Cy5.5-
HER-NFP, at a different density of H/N ratio (4:1, 10:1 and 20:1), in PBS buffer (10 mM, 100 
µL) were then added to the chambers. All HER-NFP preparations were normalized to same 
concentration of Herceptin (200 nM). After 12 hr of incubation, the cells were imaged under a 
fluorescent microscope (Olympus IX-81, Melville, NY). The cell nucleus was also 
counterstained with DAPI staining (1 µg/mL) (Invitrogen, Carlsbad, CA).  
3.3.12. Determination of cytotoxicity of HER-NFP 
MTS assay was performed according to the manufacturer’s recommendation (Promega, 
Madison, WI). All cancer cells (3,000 cells/well) were seeded on a 96-well plate and allowed to 
attach for 24 hr. Herceptin (67 nM), HER-NFP (H/N: 67/6.7 nM), IgG-NFP (H/N: 67/6.7 nM), 
or NFP (6.7 nM) in McCoy’s culture media (200 µL) supplemented with FBS (5% v/v) were 
then added to the cells. At different time points, a solution of 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS reagent) was added 
(20 µL) to the wells. The absorbance was then monitored at 490 nm in a microplate reader. The 
cell viability was calculated as a percentage of cell samples incubated with the corresponding 
culture media only. 
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3.3.13. Lysosomal staining 
SKBr-3 cells were seeded on in 4-chamber slide (Thermo Fisher Scientific, Rochester, 
NY) in the McCoy’s culture media and allowed to attach for 24 hr as described in previous 
section. Either Cy5.5-Herceptin (67 nM) or Cy5.5-HER-NFP (67/6.7 nM) in McCoy’s culture 
media (200 µL) supplemented with FBS (5% v/v) were then added to the cells. After 12 hr of 
incubation, old media was discarded and the cells were washed twice with PBS buffer (10 mM, 
pH 7.4). Cells were incubated with Lyso Tracker
®
 dye (1 µg/mL), in McCoy’s culture media 
(200 µL) (Invitrogen, Carlsbad, CA) at 37
o
C for 30 min. The cells were then imaged under 
fluorescence microscope as described above. 
3.3.14. Western blot 
To perform the western blot analysis, SKBr-3 cells (1.5 x 10
6
) were seeded in a 6-well 
plate. Herceptin (H/N: 67 nM), HER-NFP (H/N: 67/6.7 nM), IgG-NFP (H/N: 67/6.7 nM), and 
NFP (6.7 nM) in McCoy’s culture media (2.5 mL) supplemented with FBS (5% v/v) were 
incubated along with the cells. After 12 hr of incubation, the old media was discarded and the 
cells were washed twice with PBS. For cell lysis, denaturation buffer (Cell Signaling 
Technology, Danvers, MA) was added (200 µL) to the cells, and the cell debris was removed by 
centrifugation (1000 rpm). The total protein concentrations in the supernatants were determined 
by a micro-BCA assay kit (Bio-Rad, Richmond, USA). The samples (20 µg, 10 µL) were then 
resolved by electrophoresis using a SDS-PAGE gel. The proteins were then transferred to a 
Hybond
TM
-P membrane (Amersham, Piscataway, NJ). The membrane was then probed with 
primary antibodies against HER-2, total AKT, phosphorylated AKT at serine 473 (p-AKT), and 
phosphorylated ERK1/2 at threonine 202/tyrosine 204 (p-ERK1/2) (Cell Signaling Technology, 
Danvers, MA). The proteins were then detected by horseradish peroxidase conjugated anti-
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mouse or anti-rabbit secondary antibody (Cell Signaling Technology, Danvers, MA) for 1.5 hr. 
The membranes were washed again with Tween 20-TBS (0.1% v/v) and the various protein 
bands were detected with ECL
TM
 Western Blot Detection Reagents (Amersham, GE Healthcare 
Bio-Sciences, Piscataway, NJ) on Blue Ultra Autorad Film (BioExpress
®
, Kaysville, UT). 
3.4. Results and discussion 
3.4.1. Synthesis of NFP platform 
The peptide constructs (mPEG-B-K(FITC)-SGASNRA-[kldl]3) were synthesized in solid 
phase peptide synthesis, assembled into 2-dimensional nanofibers, and further homogenized into 
the desired lengths as previously described [13, 214]. The number of peptides in NFP could be 
calculated based on the distance (0.47 nm) between two peptide strands in a typical β-sheet 
structure [439]. 
3.4.2. Determination of number of amino functional groups available for bioconjugation 
NFP consisted of multiple -NH2 and -COOH groups contributed by the side chains of the 
lysine and aspartic acid residues, respectively. Theoretically, NFP could provide a maximum of 
639 reactive sites for each of the two functional groups. To determine the number of -NH2 groups 
available for bioconjugation, a 2,4,6-trinitrobenozene sulfonic acid (TNBSA) assay was 
performed (Fig. 18). TNBSA reacted with the -NH2 groups to form TNBSA-NFP adduct that 
could be monitored by an increase in the absorbance at 335 nm [440]. Using the TNBSA assay, 
we calculated there was only 60% of the -NH2 groups reacted to the TNBSA. On the other hand, 
a maximum of 35% -NH2 groups were available for reacting with Cy5.5 N-hydroxysuccinimide 
ester (Fig. 19). Overall, our results suggested that some of the -NH2 groups could be hindered by 
the bulky mPEG presented in the NFP and that the degree of couplings might depend on the 
molecular size of the reactant. 
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Fig. 18. Synthetic scheme of conjugation of 2,4,6-trinitrobenzenesulfonic acid (TNBSA) to 
nanofiber precursor (NFP). 
 
 
 
Fig. 19. Synthetic scheme of conjugation of Cy5.5 NHS ester with nanofiber precursor (NFP). 
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3.4.3. Synthesis and characterization of Herceptin-NFP conjugate (HER-NFP) 
Next, we attached Herceptin, an antibody against HER-2 overexpressing metastatic breast 
cancer, to the NFP (Fig. 20). A previously described sodium periodate oxidation was employed 
as the bioconjugation chemistry [441]. This method gave the advantage to conserve the binding 
affinity of antibody after reaction [442, 443]. 
 
 
Fig. 20. Design and synthesis of HER-NFP. (A) The peptide construct of HER-NFP was 
composed of a self-assembly peptide sequence (kldlkldlkldl), a linker peptide sequence 
(SGASNRA), methoxypolyethylene glycol (mPEG), and a fluorescence label (FITC). The 
nanofiber (NFP) was assembled from multiple NFP peptides (mPEG-BK(FITC)SGASNRA-
[kldl]3-NH2) and had multiple –NH2 groups originated from lysine residues for bioconjugation. 
(B) A synthetic scheme of HER-NFP. 
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The resulting conjugate (HER-NFP) was purified by dialysis. The total number of NFP in 
the stock solution was determined by absorbance (Fig. 21), according to the extinction 
coefficient of fluorescein isothiocyanate in 95% methanol (65,000 M
-1
cm
-1 
at 500 nm). The 
amount of Herceptin was quantified with micro-bicinchoninic acid (BCA) protein assay (Fig. 
21B) [444]. 
 
Fig. 21. Determination of molar ratio of NFP peptide to Herceptin. (A) Absorbance spectra of 
Herceptin (250 nM), NFP (5 µM) and HER-NFP (250 nM). The concentrations of indicated 
samples were based on Herceptin. (B) The amount of antibody was determined by Micro-BCA 
assay. 
Electrophoresis was then performed to confirm that Herceptin was covalently attached to 
the nanofiber. After electrophoresis, HER-NFP appeared as a single band showing a significantly 
higher molecular weight than Herceptin. HER-NFP was pure, as no unconjugated Herceptin was 
found (Fig. 22A and 23). The fact that HER-NFP band was not found in a physical mixture of 
Herceptin and NFP further suggesting that Herceptin was covalently conjugated to the surface of 
the HER-NFP.  
To confirm HER-NFP displayed in a multivalent format, immuno-gold staining was 
performed using secondary anti-human IgG-conjugated gold nanoparticles (Fig. 22B). The 
transmission electron microscopy images of immuno-stained HER-NFP revealed that multiple 
antibodies were attached on the nanofiber (Fig. 22C). On the contrary, there was no staining 
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observed when control anti-mouse IgG-conjugated gold nanoparticles were used (Fig. 22C). The 
valency of the HER-NFP could be adjusted either by attaching more Herceptin to the nanofiber 
(data not shown) or using the nanofiber with a longer length (Fig. 22C).  
 
Fig. 22. Characterization of HER-NFP. (A) A comparison of the molecular weights of Herceptin 
(300 nM), NFP (6 µM), HER-NFP (H/N ratio: 300/30 nM), and a physical mixture of Herceptin 
(300 nM) and NFP (30 nM) by electrophoresis. The gel was stained with Coommassie Blue 
solution prior to imaging. (B) A schematic diagram showing the immuno-gold staining of HER-
NFP. (C) The TEM images of (a) HER-NFP only (100 nm), (b) HER-NFP stained with 
secondary anti-human IgG-conjugated gold nanoparticles, and (c) HER-NFP stained with 
secondary anti-mouse IgG-conjugated gold nanoparticles. (d) A control TEM image showing a 
suspension of secondary anti-human IgG-conjugated gold nanoparticles. (e) A TEM image of 
HER-NFP (1-2 µm) stained with secondary anti-human IgG-conjugated gold nanoparticles and 
(f) HER-NFP stained with secondary anti-mouse IgG-conjugated gold nanoparticles. The 
nanofibers were negatively stained with uranyl formate in water (2% w/v). 
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Fig. 23. Herceptin was covalently attached to HER-NFP. Optical images of SDS-PAGE gels 
loaded with different concentrations (nM) of (A) Herceptin and (B) HER-NFP.  
 
3.4.4. Investigation of the Herceptin density on cellular uptake 
Studies have shown that the density of antibody appeared on a nanoparticle surface could 
affect the rate as well as the degree of cellular internalization [445-447]. To investigate the effect 
of the density antibody on cellular uptake, HER-NFPs composing of different Herceptin-to-
nanofiber (H/N) ratio (2:1 to 20:1) were synthesized. All the nanofibers were also labeled with 
the same amount of Cy5.5 for quantifications. As expected from the multivalent effect, 
increasing the number of Herceptin antibodies (from 2 to 10) attached to the nanofibers would 
enhance the cellular uptake and, thus, the amount of antibody (Fig. 24A).  An optimum cellular 
uptake of Herceptin (4.5 pg /cell) was observed in the preparation with an H/N ratio of 10:1. 
However, further increasing the H/N ratio to >10 did not enhance the cellular uptake, possibly 
because of steric hindrance (Fig. 24A). 
Next, we investigated the intracellular distribution of the Cy5.5-labeled HER-NFP by 
fluorescence microscopy (Fig. 24B). There was no significant difference in terms of the 
localization among all the nanofibers, which indicated that they were taken up by SKBr-3 cells 
through the same mechanism [448]. The nanofibers appeared as discrete fluorescence spots in 
the cytoplasm, which were co-localized with the lysosome staining (Fig. 24B).  
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Fig. 24. A comparison of internalization of HER-NFP loaded with different density of Herceptin 
in SKBr-3 cells. (A) Amount of Herceptin internalized (pg/mL) in cells incubated with HER-
NFP of different loading (2, 4, 10 and 20 Herceptin per nanofiber) at 12 hr. (B) Cellular 
distribution and localization of different of loading of HER-NFP at H/N ratio 4:1, 10:1 and 20:1. 
(C) Amount of Herceptin internalized in cells incubated with H/N ratio10:1 HER-NFP at various 
time points (2, 4, 8, 12 and 24 hr.). 
 
These above results suggested that the HER-NFP’s were possibly internalized into the 
cells via receptor-mediated endocytosis.  Interestingly, both the Cy5.5-labeled HER-NFPs and 
Herceptin shared similar kinetics of cellular uptake (Fig. 24C), but the amount of antibodies 
inside the cells was significantly higher (>2-fold) in the case of Cy5.5-labeled HER-NFP. 
3.4.5. The effect of the length of nanofiber on cellular uptake  
The endocytosis of an antibody-conjugated nanoparticle is dependent on its ability to 
cross-link the cell-surface receptors and, subsequently, to create an in-folding of the cell 
membrane [449]. This process can be influenced by the size, shape, and surface characteristics of 
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a particle [450-452]. Here, we investigated whether the internalization of HER-NFP could be 
affected by its length. Experiments were performed for determining the cellular uptake, by 
adding various Cy5.5-labeled HER-NFP of the same H/N ratio (10:1), but with different lengths 
(50 nm, 100 nm, 400 nm, and uncut), to the SKBr-3 cell lines (Fig. 25). 
 
 
Fig. 25. A comparison of internalization of different size HER-NFP in SkBr-3 cells. (A) Amount 
of Herceptin internalized (pg/mL) in cells incubated with 50 nm, 100 nm, 400 nm and uncut 
HER-NFP. (B) Dependence of internalization of HER-NFP on its concentration. Amount of 
Herceptin internalized (pg/mL) in cells incubated at 0, 5, 10, 20, 40 and 80 µg/mL HER-NFP 
(H/N: 10:1) for 12 hr. 
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Our results demonstrated that all NFP conjugates regardless of the size efficiently 
delivered more antibodies inside the cells as compared to the Herceptin alone (Fig. 25A). The 
optimal length of nanofiber was 100 nm, since it revealed the maximum cellular uptake. As 
expected, increasing the amount of Cy5.5-labeled HER-NFP during incubation would enhance 
the cellular internalization of Herceptin (Fig. 25B).  However, there was no further enhancement 
at a higher concentration, possibly because of the cell-surface HER2 were saturated from the 
bindings. Overall, our data suggested that a NFP conjugated with ten antibodies and of 100 nm in 
length was the optimized preparation and, thus, was employed for the rest of our studies.  
3.4.6. The enhanced cytotoxic effect of HER-NFP 
Next, MTS assay was performed to compare the cytotoxicity of HER-NFP and Herceptin 
in SKBr-3, MCF-7, and MDA-MB-231 breast cancer cell lines. These cell lines expressed 
various levels of HER2 (Fig. 26A). NFP was confirmed to be intrinsically nontoxic (Fig. 26B). 
On the other hand, HER-NFP was more effective than Herceptin in inhibiting cell growth of 
HER2-positive SKBr-3 cells. At 72 hr after incubation, 80% of the cells treated with Herceptin 
were viable while it was only 40% in the case HER-NFP. The enhanced cytotoxic effect of HER-
NFP was specific, as it did not induce toxicity towards the HER-2 negative MCF-7 and MDA-
MB-231 cell lines (Fig. 26C and D). Furthermore, the control IgG-NFP was unable to inhibit any 
cell growth. Our results indicated that the cytotoxicity of Herceptin could be enhanced by 
converting the antibody into a multivalent format using NFP [372, 419]. 
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Fig. 26. The cytotoxicity of HER-NFP was specific. (A) A western blot showing the HER-2 
expressions of SKBr-3, MCF-7 and MDA-MB-231 cell lines. MTS assays were performed to 
determine the percentage of cell viability of (B) SKBr-3, (C) MCF-7, and (D) MDA-MB-231 at 
different time points (hr) after treatment with Herceptin (67 nM), HER-NFP (H/N ratio 67/6.7 
nM), IgG-NFP (H/N ratio 67/6.7 nM), or NFP (6.7 nM) in McCoy’s culture media (200 µL). All 
the data was presented as an average of three independent experiments. 
3.4.7. Modulation of cell signaling pathway by HER-NFP 
The underlying mechanism(s) of Herceptin is not completely clear. It was proposed that 
Herceptin could exhibit its anti-tumor activity indirectly through the induction of various 
immunological responses including antibody-dependent cytotoxicity and complement-dependent 
cytotoxicity [453] and/or directly by modulating the downstream cell signaling pathways that 
involving in cell proliferation, invasion, and survival [454-456]. Recent studies have shown that 
a multivalent format of the Herceptin could promote the cytotoxic effect by further blocking 
some of the essential cell survival pathways, including the phosphatidylinositol 3-kinase (PI3K) 
and the mitogen activated protein kinase (MAPK) pathways, through clustering more of the 
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antigen/antibody complex [419]. As expected, when SKBr-3 was treated with Herceptin, both 
the phosphorylation of AKT (at Serine 473) and the phosphorylation of ERK1/2 (at Threonine 
202/Tyrosine 204) decreased with time (Fig. 27A and B) but with the effect was more profound 
in HER-NFP, which indicated that the enhanced cytotoxic effect of HER-NFP could be 
attributed to further downregulation of both the PI3K and MAPK pathways [372, 419]. 
 
Fig. 27. HER-NFP downregulated certain cell survival signaling pathways. (A) Western blots 
showing the total AKT, p-AKT, and p-MAPK expressions in SKBr-3 cell lines at different time 
points (hr) after treatment with Herceptin (67 nM) or HER-NFP (H/N ratio 67/6.7 nM). (B) A 
comparison of the protein expressions in SKBr-3 cell at 6 hr after treatments with PBS, 
Herceptin (67 nM), HER-NFP (H/N ratio 67/6.7 nM), IgG-NFP (H/N ratio 67/6.7 nM), or NFP 
(6.7 nM). (C) Western blots showing the HER-2 expressions in SKBr-3 cell lines at 12 hr after 
treatment with Herceptin (67 nM) or HER-NFP (67/6.7 nM). 
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3.4.8. Downregulation of HER-2 expression by HER-NFP 
Here, we compared the HER-2 levels in the SKBr-3 cell lines after treatment with 
Herceptin and HER-NFP. At 48 hr, we observed a marginal decrease of the HER-2 in the cells 
treated with Herceptin. In contrast, there was a significant reduction of the HER-2 level in the 
cells treated with HER-NFP.  
Our cellular imaging data demonstrated that there was more cellular uptake of HER-NFP 
than the Herceptin, and that HER-NFP were predominantly localized at the lysosomes rather 
than distributed evenly throughout the cytoplasm after cellular internalization (Fig. 28). 
Therefore, it is possible that the enhanced cytotoxic effect of HER-NFP was caused by a 
downregulation of HER-2 via an increase in the endocytosis and degradation of the 
antigen/antibody complex [457] which ultimately prevented the recycling of HER-2 to the cell 
surface. 
 
Fig. 28. The cellular distribution of HER-NFP. SKBr-3 cells were treated with either Herceptin 
(200 nM) or HER-NFP (H/N ratio 200/20 nM) that labeled with Cy5.5 for 6 hr at 37oC and 
followed by addition of Lyso-Tracker
®
 (green). The nuclei were counterstained with DAPI 
staining solution (blue). 
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3.5. Conclusion 
Various strategies have been proposed to increase the effectiveness of a monoclonal 
antibody [458-460]. In the present study, we successfully employed a new type of peptide 
nanofiber (NFP) as a multivalent platform. All the components of NFP are non-toxic and 
hemocompatible since the employed PEG is known to be non-toxic and non-immunogenic and 
the self-assembly peptide sequence (kldlkldlkldl) has been used for tissue engineering [461]. 
Furthermore, NFP consists of multiple amino functional groups on the surfaces, which allowed 
further attachment of various ligands for targeted delivery. Here, we covalently conjugated 
approximately ten Herceptin antibodies to one nanofiber and demonstrated that the resulting 
HER-NFP was more effective in inhibiting SKBr-3 cell growth than the free Herceptin. This 
enhanced cytotoxic effect could be explained by the multivalency which promoted direct 
inhibitions of the downstream cell survival PI3K and MAPK pathways via an increase in the 
clustering of the antigen/antibody complex or indirectly downregulated the cell surface HER-2 
via an increase in the internalization and degradation, rather than the recycling, of the receptor. It 
is noteworthy that peptide-based nanofibers have been used as carriers for chemotherapeutic 
agents [216, 408-410]. The co-delivery of tumor-targeted antibody would provide an additional 
benefit to optimize therapeutic efficacy in cancer treatments in the future.  
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CHAPTER 4. UPREGULATION OF UROKINASE PLASMINOGEN ACTIVATOR IN 
PROSTATE CANCER CELLS OVEREXPRESSING 15-LIPOXYGENASE-1 
4.1. Abstract 
Proteases, such as urokinase plasminogen activator (uPA) are often involved in cancer 
growth and invasion due to their ability to degrade the extracellular matrix. Several studies have 
indicated that lipid-peroxidizing enzymes, such as lipoxygenases may act an upstream molecule 
in the activation of variety of signaling pathways that may be involved in the progression of 
cancer. Of all studies documented, the investigation of 15-lipoxygenase-1 (15-LOX-1) is 
particularly interesting because this enzyme acts as a tumor suppressor in most cancers, however 
behaves very differently in prostate cancer (demonstrating a strong pro-carcinogenic role).  In the 
present study, we provide evidence for the first time that indicates the role of 15-LOX-1 in the 
upregulation of urokinase plasminogen activator (uPA), a cancer related protease. For proof of 
concept, we selected prostate cancer PC-3 cells which were transfected with 15-LOX-1 as a 
model for our studies.  Our data demonstrated that there was upto five-fold increase in mRNA as 
well as protein expression of uPA in 15-LOX-1 transfected cells (15-LOX-1/PC-3) as compared 
to parental PC-3 cells. The mechanism of upregulation of uPA was explained through the 
activation of various subfamilies of the MAPK pathway, especially the stress-activated JNK1/2 
pathway. In summary, our data supports previous studies that 15-LOX-1 has a pro-carcinogenic 
role in prostate cancer. Furthermore, we believe that the information about the link between of 
lipoxygenase family of enzymes and cancer-related uPA enzyme would help us to identify new 
strategies to target prostate cancer more effectively. 
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4.2. Introduction 
4.2.1. PUFAs and prostate cancer 
Prostate cancer is the most common malignancy and the second leading cause of cancer 
death among men in the United States [462]. Ecological and epidemiological studies have 
revealed there are large differences in rates development of prostate cancer between different 
ethnic regions [463]. Dietary fat consumption had been positively linked to prostate cancer 
development [464, 465]. African-Americans are at higher risk of developing prostate cancer than 
non-Hispanic whites [466]. Interestingly, omega-3 (n-3) polyunsaturated fatty acids have been 
associated with decreased risk of developing prostate cancer whereas positive association 
between alpha-linolenic acid and advanced and fatal prostate cancer [467]. 
4.2.2. Polyunsaturated fatty acids (PUFAs) 
Polyunsaturated fatty acids or “PUFA” belong to the class of simple lipids. They are 
termed “polysaturated” because these fatty acids contain multiple carbon-carbon double bonds. 
The classification of PUFAs is further based on the position of the first carbon-carbon double 
bond with respect to the methyl group termini. Omega-3 PUFA has double bond between third 
and fourth carbons, whereas omega-6 PUFA have double bond between sixth and seventh 
carbon. 
In mammals, two types of PUFA, Linoleic acid (n-6) (LA) and alpha-linolenic acid (n-3) 
(LNA) cannot be synthesized by humans and therefore are acquired through diet [468]. Since 
these fatty acids have important biochemical roles, they are usually referred as essential fatty 
acids (EFA) [469, 470]. Fatty acids may interconvert to other fatty acids, for example linoleic 
acid converts into arachidonic acid (AA), which acts as a precursor for different eicosanoids 
[471].  
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Omega-3 fatty acids, includes alpha linolenic acid which is abundant in fish oil and green 
leafy vegetables, such as spinach, flax seed oil, walnuts [468, 472]. Examples of other omega-3 
fatty acids are eicosapentaenoic acid (EPA), docosahexanoic acid (DHA) and eicosatetranoic 
acids (ETA). On the other hand, omega-6 fatty acids includes linoleic acid (LA), one of the most 
important fatty acid of this group and  is main component of safflower oil, corn oil, sunflower oil 
and soybean  oil. Ratio of omega-3 and omega-6 fatty acids is important for maintaining normal 
physiological conditions [473]. Other omega-6 fatty acids are gamma-linolenic acid (GLA), 
arachidonic acid (AA) and dihomo-gama-linolenic acid (DLGA). 
4.2.3. Relationship between polyunsaturated fatty acids and cancer 
Polyunsaturated fatty acids (PUFAs) are important components of the cells. They are 
important component of diet and play an important role in maintaining cell membrane structure, 
cell signaling and regulation of gene expression [474]. Evidence suggests that individual PUFA’s 
may play a role in cancer progression, especially in the development of breast [475], prostate 
[476, 477] and colon cancer [478, 479].  Therefore, PUFA’s have been proposed to be useful as 
chemotherapeutic agents or as adjuvant to radio- or chemotherapy for cancer treatment. 
Alternately, some PUFA’s have been known have a protective role in cancer development [480]. 
Although there are many studies which implicate the role of PUFA in cancer development, there 
is still no epidemiological evidence to confirm this.  
4.2.4. Type of PUFA and cancer development 
Type of PUFA may be crucial developing risk for cancer development. Monosaturated 
and n-3 PUFA may have a protected role in cancer development [481]. On the other hand, n-6 
PUFAs are thought to be positively correlated with cancer development [467].  In general, the 
most selective cytotoxic effects have been obtained with the three eicosanoid precursors, GLA, 
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AA and EPA, intermediate effects were observed with LA and ALA, and least effects were 
observed with DHA [482-486]. Cytotoxic effect may be dependent on the number of double 
bonds. Studies indicated that PUFA containing 3, 4 and 5 double bonds are more effective than 
PUFAs with 2 and 6 double bonds [483]. Animal model fed with strict controlled diets have been 
utilized to understand relationship PUFAs and cancer development [487], however, there are 
difficulties in transference of outcome when rodent system is compared to human system. Till 
now, it is generally accepted that factors such as increase in oxidative stress, ability to 
metabolize fatty acids and cause changes in membrane integrity may influence cell signaling 
pathways that may result in cancer growth or apoptosis [488]. 
4.2.5. Lipoxygenases 
Lipoxygenases (LOXs) are a family of enzymes that oxidize polyunsaturated fatty acids 
to form biologically active metabolites [489].  The metabolism of polyunsaturated fatty acids is 
strongly regulated by two classes of lipid peroxidation enzymes, the lipoxygenases and 
cyclooxygenases [490, 491]. Depending on the position of inserting oxygen in substrate, these 
enzymes generate different products. The cyclooxygenase (COXs) are actively involved in the 
conversion of arachidonic acid to prostaglandins (PGs) [492], whereas the lipoxygenases are 
involved in the conversion of arachidonic acid and linoleic acid into hydroxyoctadecadienoic 
acid (HODE), and hydroperoxyeicosatetraenoic acid (HETE) metabolites respectively [60]. 
There are a total of eight lipoxygenases (5-, 8-, 9-, 10-, 11-, 12-, 13- and 15-) identified, 
depending on the position of peroxidation of polyunsaturated fatty acids [493]. In animals, there 
are four lipoxygenases 5-, 8-, 12-, and 15-LOX. Lipoxygenases catalyse the insertion of oxygen 
at carbon 5, 8, 12 and 15 position of arachidonic acid resulting in formation of products 5S-, 
12S-, or 15S-hydroperoxyeicosatetraenoic acid (5-, 8-, 12-, or 15-HPETE), which are reduced 
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further to their hydroxyl forms (5-, 8-, 12-, 15-HETE) by glutathione peroxidase enzyme [59, 
494]. These enzymes mainly catalyze pathways from membrane lipids to signaling molecules. 
Phospholipase cleaves the membrane lipid to form polysaturated fatty acids (Fig. 29). 
 
Fig. 29. Synthetic scheme showing metabolism of arachidonic acid by lipoxygenases. The 
lipoxygenases5-LOX, 8-LOX, 12-LOX and 15-LOX resulting in the formation of metabolites 5-
HPETE, 8-HPETE, 12-HPETE and 15-HPETE, respectively. 
Arachidonic acid, linoleic acid, and linolenic acid are some of the important LOX 
enxymes. The 5-LOX pathway leads to the formation of 5 (S)-HETE and leukotrienes, whereas 
the 12- and 15-LOXs can form 12- and 15-HETE, respectively. The lipoxygenases and their 
metabolites have been strongly implicated for their role in inflammation, immunity, and also in 
other pathological conditions such as cancer, atherosclerosis, asthma, and ulcerative colitis [495]. 
4.2.6. Role of lipoxygenases in cancer 
The expression of LOXs has found to be upregulated in some types of cancer, and has 
been associated with stimulation of cell growth, induction of mutations, inhibition of apoptosis, 
and cell invasion [496]. For example, metabolites of 5-LOXs in the arachidonic acid pathway 
can enhance cancer cell growth. 5(S)-HETE, a major metabolite of 5-LOX is involved in 
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stimulating proliferation of pancreatic cancer cells through the activation of mitogen activated 
protein kinases (MAPK) pathway [497]. The formation of reactive oxygen species (ROS) 
through the degradation of lipid in membranes can also trigger downstream signaling events that 
lead to the transcription of genes such as NF-kappa B and peroxisome proliferator-activated 
receptors (PPAR). The LOX signaling can also capable of causing mutations in target genes. 5-
LOX product LT4 forms adducts with DNA bases, suggesting that it may serve as modulator of 
transcription [498]. 
4.2.7. 15-Lipoxygenase-1 (15-LOX-1) 
15-Lipoxygenase-1 (15-LOX-1) is one of the two isoforms of 15-LOX that differ in 
tissue distribution and substrate preference [59] and is expressed in reticulocytes [499], 
eosinophils [500], macrophages [501], mast cells [502], and bronchial epithelial cells [503]. On 
the other hand, 15-LOX-2 can be found in tissues such as prostate gland [504], cornea [505], 
skin, and keratinocytes [506]. 15-LOX-1 functions to converting the substrate, linoleic acid, into 
its metabolite, 13-(S)-hydroxyoctadecadienoic acid (13-HODE) [507]. Fig. 30 shows the 
synthetic scheme of 15-LOX-1 mediated conversion of arachinonic acid and linoleic acid into 
15-HPETE and 13-HPODE, respectively. Studies have shown that 15-LOX-1 and 13-HODE 
were involved in certain diseases including cancer [60-62], inflammatory disorders [500, 508-
510], atherosclerosis [511], and angiogenesis [512]. For example, 15-LOX-1 was shown to 
increase metastasis of cancer cells to lymph nodes in mammary carcinoma xenograft [513]. It 
was also found overexpressing in Hodgkin lymphoma derived L-1236 cells [514]. On the other 
hand, 13-HODE can induce mitogenic response in human breast cancer BT-20 cells [515].   
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Fig. 30. Synthetic scheme showing the 15-LOX-1 mediated conversion of PUFA’s. Arachidonic 
acid and linoleic acid were conversted into 15-HPETE and 13-HPODE respectively. 
4.2.7.1. Role of 15-LOX-1 in prostate cancer 
In prostate cancer, there is a strong evidence to suggest that 15-LOX-1 is pro-
tumorigenic. Studies have shown that the expression of 15-LOX-1 in prostate cancer tissue was 
much higher as compared to normal prostate tissue and the level was correlated with the Gleason 
score [516]. In vitro studies demonstrated that 13-HODE increased cell growth in PC-3 cells, and 
the addition of specific inhibitor of 15-LOX-1, PD146176 reversed this effect in a dose-
dependent manner [61]. In vivo studies demonstrated that PC-3 cells overexpressed with 15-
LOX-1 resulted in a greater number of tumors and larger volume as compared to parental PC-3 
cells [61]. Taken together, this data suggested a contributory role of 15-LOX-1 in cell growth 
and proliferation in prostate cancer.  
4.2.7.2. Role of 15-LOX-1 in colon cancer 
The role of 15-LOX-1 in cancer development has been controversial, as there are a 
number of studies that also demonstrate its anti-tumorigenic effect, particularly in colon cancer 
[517-520]. 15-LOX-1 expression was down-regulated in colorectal adenomas [521], and the 
restoration of 15-LOX-1 in colon cancer xenografts cell lines induces formation of apoptotic 
proteins [522]. The anti-tumorigenic effect of 15-LOX-1 has also been observed in other forms 
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of cancer such as esophageal cancer [523], gastric cancer [524], bladder cancer [525], pancreatic 
cancer [526], breast cancer [527] and glioma [528].  
4.2.8. Urokinase plasminogen activator 
uPA is a 54 kDa serine protease which consists of three conserved domains, a growth 
factor domain, a kringle domain and a serine protease domain. It is secreted as a zymogen (pro-
uPA), which gets activated upon binding to its receptor uPAR [529]. The active uPA converts 
plasminogen to plasmin, which can act on broad range of substrates and leads to the activation of 
growth factors [530, 531]. Plasmin acts on degrades fibrin, fibronectin, vitronectin, and laminin 
[532, 533]. The binding of uPA to uPAR also facilitates signaling events involving integrins, 
growth factors, receptors associated with cell growth and proliferation, angiogenesis and cell 
adhesion [534]. The turnover rate of uPA is tightly controlled by PA1 and PA2, which are 
endogeneous inhibitors of uPA [63, 535]. Both PA1 and PA2 can counterbalance the activity of 
uPA by forming stable 1:1 complexes. PA1 is thought to be the primary inhibitor of uPA, and its 
levels are also upregulated in cancer [63, 536].  
4.2.9. MAPK pathway 
The MAPK Pathway is one of the most important pathways which is actively involved in 
the transduction of signals from cell membrane to the nucleus [537, 538]. These consist of 
protein serine/threonine kinases and can be divided into three well defined groups: the 
extracellular signal regulated kinases (ERK 2 c-Jun) N-Terminal kinases (JNK 1, JNK 2, JNK 3) 
and p38 MAPK [539]. All subfamilies of MAPK pathway are involved in the regulation, growth, 
and survival of normal cell proliferation [540]. For example, the ERK pathway is activated by 
MEK, which in turn is activated by RAS. RAS is MAP3K protein kinases, which is downstream 
of growth receptors such as tyrosine kinases and epidermal growth factor [541]. Various growth 
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factors bind to these receptors and induce their dimerization and activation [542]. In mammalian 
systems, three subfamilies of MAPK signaling units have been identified, the extracellular 
signal-regulated kinases (ERKs) [543], the c-Jun amino-terminal kinases (JNKs; also referred to 
as stress-activated protein kinases (SAPKs) [544] and the p38 MAPKs (p38s) [545, 546]. The 
MAPK pathway has emerged as an important target in cancer therapeutics [541]. Individual 
members of MAPK family require specific stimuli to become activated and the activated form of 
the proteins further act on their substrates. Intracellular cascade to cell proliferation, survival, 
angiogenesis and migration [547]. 
4.2.10. The role of MAPK pathway in the upregulation of uPA 
Numerous studies have indicated that tumor cells produce large amounts of oxygen 
species as compared to normal cells [548, 549]. In some studies it is indicated that reactive 
oxygen species contribute to invasive ability of cells by regulating the levels of tumor associated 
proteases such as uPA [550, 551]. This process involves activation of multiple signaling 
pathways including the phosphorylation cascade of MAPK family. The hepatocyte growth factor 
(HGF) is a multipotent growth factor which is normally secreted by mesenchymal cells [552]. A 
recent study indicated that HGF activated in human hepatoma cells lines HEPG2 and HEPG3 
lead to production of ROS, which resulted in activation of MAPK pathway [553]. The activation 
of MAPK pathway further led to upregulation of uPA in these cells [553]. Thus, there may be 
some role of MAPK pathway in the upregulation of uPA. 
4.3. Material and methods 
4.3.1. Materials 
The 15-LOX-1 inhibitors PD146176 and nordihydroguaiaretic acid (NDGA) were 
purchased from Cayman Chemicals (Ann Arbor, MI).  Stock solutions of inhibitors (10 mM) 
86 
 
were made in dimethylsulfoxide (DMSO) and stored at -20oC until use. ERK 1/2 
inhibitor (U1026) was obtained from Cell Signaling Technology (Danvers, MA). p38 MAPK 
inhibitor (SB203580) and SAPK/JNK inhibitor (SP600125) were obtained from Cayman 
chemicals (Ann Arbor, MI). Primary antibodies specific to ERK1/2 phosphorylated at 
Thr202/Tyr204 (pERK 1/2), p38 MAPK phosphorylated at Thr180/Tyr182 (p38MAPK), and 
SAPK/JNK phosphorylated at Thr183/Tyr185 (p-SAPK/JNK) were purchased from Cell Signaling 
Technology (Danvers, MA). Secondary antibody conjugated to horseradish peroxidase (HRP) 
was also purchased from Cell Signaling Technology (Danvers, MA). Monoclonal antibodies 
specific to uPA and 15-LOX-1 were purchased from Abcam (Cambridge, MA). 
4.3.2. Cell culture 
Human prostate cancer cells PC-3 were purchased from ATCC (Manassas, VA). PC-3 
cells transfected with 15-LOX-1 (15-LOX-1/PC-3 cells) were provided as a generous gift from 
Dr. Steven Qian (North Dakota State University, North Dakota). Both PC-3 and 15-LOX-1/PC-3 
cells were grown in RPMI-1640 growth medium supplemented with fetal bovine serum (FBS) 
(10% v/v). The RPMI-1640 growth medium was purchased from Hyclone Laboratories (Logan, 
UT) and FBS was purchased from Mediatech Inc. (Manassas, VA). All culture media were 
supplemented with antibiotics such as penicillin G (100 U/mL) and streptomycin (0.1 mg/mL), 
purchased from ATCC (Manassas, VA). In some experiments, we used serum-free and phenol-
red free media which was obtained from Hyclone Laboratories (Logan, UT).  All cells were 
cultured in incubators at 37
o
C with 5% CO2 under humidified conditions. Culture media of 15-
LOX-1/PC-3 cells was supplemented with Zeocin (50 μg/mL), purchased from Invitrogen 
(Carlsbad, CA). 
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4.3.3. Migration assay 
The migration assay was performed using transwell invasion chambers (BD Biosciences, 
San Jose, CA) of 24-well plate with an 8 µm pore size polycarbonate filter. PC-3 cells, 15-LOX-
1/PC-3 cells alone, or in combination with NDGA was analyzed for their migratory potential. All 
cells were trypsinized, washed, and suspended in serum-free media. Aliquots of cells (1 x 
10
4
/well), in serum-free media (200 µL) were transferred to the inner side of invasion chamber 
and allowed to attach overnight in incubator at 37
o
C. The outer side of the chamber was 
incubated with culture media (300 µL) containing FBS (10% v/v). After 12 hr of incubation, the 
supernatant in the inner side of the chamber was discarded and cells were treated with NDGA (5 
µM) in serum-free media (200 µL). Cells treated with dimethylsulfoxide (DMSO) (0.01% v/v) 
diluted in media (200 µL) were treated as controls. The plate was then transferred to the 
incubator and incubated for additional 24 hr. at 37
o
C. After incubation, non-migrated cells in the 
inner side of the transwell membrane were removed using cotton swabs. Cells that had migrated 
through the membrane were fixed by incubating the filter in paraformaldehyde solution (3.7% 
w/v) in PBS buffer at room temperature for 30 min. The cells were washed twice with PBS 
buffer and visualized by staining with crystal violet (0.005% w/v) in PBS buffer. Under 4X 
magnification, 4 randomly selected fields were examined using optical microscope (Am Scope 
Microscopes, Irvine, CA) and the number of migrated cells were calculated by staining with 
crystal violet (0.005% w/v) in PBS buffer.  
4.3.4. Wound healing assay 
PC-3 and PC-3-LOX cells were seeded in 6-well plate and incubated until they were 80-
90 % confluent.  Some cells were treated and NDGA (5 µM) in serum free media (5 mL). A 
scratch was carefully made in the monolayer of cells with a sterile pipette tip (100 µL size). The 
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cells were washed once with PBS (10 mM, pH 7.4) to remove debris and incubated in culture 
media (2.5 mL) containing FBS (10% v/v). The cells were immediately photographed under the 
microscope (Olympus IX-81, Melville, NY) and the distances between wound edges were 
measured with a ruler. The plate was transferred to the incubator and incubations were 
performed for 4, 8, 12 and 24 hr. at 37
o
C. At each time point, number of cells that migrated per 
mm
2
 area from the wound edges into the cell free zone was counted.  
4.3.5. siRNA transfection 
Small interfering RNA’s (siRNA’s) for 15-LOX was purchased from Dharmacon 
(Lafayette, CO). The siRNA for 15-LOX consisted of a pooled mixture of four SMART-selected 
siRNA duplexes. For siRNA transfection, PC-3 cells were seeded (1 x 10
5
 cells per well) in 6-
well plate in culture media containing FBS (1% v/v). We used antibiotic free media throughout 
our siRNA transfection studies. PC-3 cells were then transfected with 15-LOX siRNA using 
Lipofectamine 2000 (Invitrogen, Carlsbad, CA). Briefly, siRNA (100 nM, 5 µL) and 
Lipofectamine 2000 (5 µL) were separately diluted in culture medium (250 µL) containing FBS 
(1% v/v), and allowed to incubate at room temperature for 15 min. The solutions were mixed, 
incubated for additional 20 min. The mixture (500 µL) was diluted with an equal volume of 
culture media (500 µL) and incubated with the cells in incubator at 37
o
C. The cells were further 
allowed to incubate with siRNA’s for additional 24 hr and harvested for analysis. 
4.3.6. RT-PCR 
The mRNA expression of uPA was determined by real-time reverse transcriptase 
polymerase chain reaction (RT-PCR) using Stratagene Mx 3000 Real-Time PCR System 
(Agilent Technologies, Santa Clara, CA). RNA was extracted using PureLink
TM
 RNA Mini Kit 
(Invitrogen, San Francisco, CA) and the samples were kept in ice. The concentration of total 
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RNA was quantitated by measuring the absorbance at 260 nm using the extinction coefficient (25 
µL/µg/cm
-1
) in distilled water. RNA (50 ng, 20 µL) was transcribed into cDNA using AMV 
reverse transcriptase (Promega, Madison, WI) for 15 min at 60°C in Accublock Digital Dry Bath 
(Labnet International, Inc., Woodbridge, NJ). The resulting cDNA was amplified in the presence 
of SuperScript®VILO
TM
 (Invitrogen, Carlsbad, CA) and primers for either uPA or beta actin. 
Primers for both genes were purchased from Integrated DNA technologies (Coralville, IA). The 
sequences of primers for uPA were 5′-GTGGGCTGTGAGTGTAAGTGTGA-3′ (forward) and 
5′-GACTTAACAATCAGACACCAGCTCTT-3′ (reverse). The primers for beta actin were 5′-
CATGTACGTTGCTATCCAGGC-3′ (forward) and 5′-CTCCTTAATGTCACGCACGAT-3′ 
(reverse).  There were a total of 40 thermal cycling steps in the reaction. The mRNA levels 
among the test cells were analyzed by relative quantification 2
–ΔΔCt
 method [341]. PCR reaction 
was performed in triplicate. 
4.3.7. Western blot 
PC-3 and PC-3/15-LOX-1 cells were seeded (1.5 x 10
6
) in 6-well plate in RPMI-1640 
culture medium containing FBS (10% v/v). After 12 hr. of incubation, the cells were treated as 
per requirement. The old media was discarded and cells were washed with PBS (10 mM, pH 7.4) 
and lysed in lysis buffer (Cell Signaling Technology, Danvers, MA). Lysates of cells were then 
cleared at 10, 000 rpm for 5 min, and the protein concentrations with determined using Micro-
Bincinconinic acid (BCA) assay (Pierce, Rockford, IL). Proteins (20 µg, 10 µL) were then 
separated by a polyacrylamide gel electrophoresis on a sodium dodecyl sulfate-polyacrylamide 
gel (12% w/v) and transferred to a polyvinylidene difluoride (PVDF) Hybond
TM
-P membrane 
(Amersham, Piscataway, NJ).  The membrane was blocked with nonfat dry milk (5% w/v) in 
Tween 20-TBS buffer (0.1% v/v), followed by incubation with mouse-anti-human primary 
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antibodies specific for 15-LOX-1 and uPA. Primary antibodies were used to detect pERK1/2, 
p38 MAPK, pJNK1/2, and beta actin. The incubations were performed overnight at 4
o
C. The 
membranes were then washed three times with Tween 20-TBS buffer (0.1% v/v) followed by 
incubation with horseradish peroxidase (HRP)-conjugated secondary antibodies for 1 hr. The 
membranes were washed again and the bound antibody was detected using the Enhanced 
Chemiluminescence System (ECL). The protein bands were detected using Western Blot 
Detection Reagents (Amersham, GE Healthcare Bio-Sciences, Piscataway, NJ) on Blue Ultra 
Autorad Film (BioExpress
®  
Kaysville, UT). All experiments were performed in triplicate. 
4.3.8. uPA activity assay 
To perform the uPA activity assay, we employed the AssaySense Human uPA 
Chromogenic Activity Assay Kit (Assaypro, St. Charles, MO). PC-3 and 15-LOX-1/PC-3 cells 
were seeded at a density of 1x10
6
 cells in tissue culture dishes. The cells were allowed to attach 
for 12 hr and then treated with either NDGA or ALOX siRNA for additional 24 hr. Cells in 
media only were treated as controls. Conditioned media from PC-3 and 15-LOX-1/PC-3 cells, 
either alone or treated was collected, centrifuged at 1500 rpm, and concentrated with an Amicon 
Ultra-4 10k filter (Millipore, Billerica, MA).  The concentrated media (30 µL) were incubated 
with assay buffer (50 µL) and uPA substrate solution (20 µL).  The assay buffer and uPA 
substrate were provided in the assay kit. The solutions were then transferred to flat-bottom 96-
well plates and incubated in the incubator at 37
o
C. After 6 hr, the enzyme activities were 
monitored by absorbance at 405 nm. While performing the assay, we plotted a standard curve of 
known activities of uPA (between 0 and 6.25 U/mL). The activities of the supernatants were then 
interpolated from the standard curve. The experiment was performed in triplicate. 
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4.4. Results and discussion 
4.4.1. Overexpression of 15-LOX-1 in PC-3 cells upregulates uPA 
Secretion of proteases, such as urokinase plasminogen activator (uPA), is a key 
requirement for cancer cells to invade surrounding tissues [554]. We examined the possible role 
of 15-lipoxygenase-1 (15-LOX-1) in the upregulation of uPA in PC-3 cells, a prostate cancer cell 
line which has high expression of uPA [555]. Levels of 15-LOX-1 in parental and transfected 
PC-3 cells (15-LOX-1/PC-3) selected for this study were confirmed using western blot (Fig. 
31A). 15-LOX-1/PC-3 cells showed up to a four-fold increase in mRNA expression of uPA as 
compared to parental PC-3 cells (Fig 31C). The increase in expression of uPA was further 
confirmed by western blot analysis and uPA activity assay (Fig 31A).  Incubation with NDGA, 
an inhibitor of 15-LOX-1 [556], decreased the expression of uPA in 15-LOX-1/PC-3 cells, 
suggesting that 15-LOX-1 is involved in the upregulation of uPA (Fig. 31D). 
To confirm our results, we examined the effect of siRNA gene silencing in reducing the 
level of 15-LOX-1 in 15-LOX-1/PC-3 cells and parental PC-3 cells. A significant reduction in 
15-LOX-1 by siRNA was achieved in both cell lines, as determined by western blot (Fig. 31C). 
15-LOX-1/PC-3 cells had a significant reduction in uPA upon incubation with the siRNA (Fig. 
31D). However, reduction of 15-LOX-1 in PC-3 cells did not appreciably affect the expression 
of uPA (Fig. 31D). The fact that gene silencing with siRNA could not result in reduction of uPA 
in PC-3 cells may indicate that basal level of uPA in normal PC-3 cells is not sufficient to 
activate downstream signaling pathways that upregulate uPA expression. 
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Fig. 31. The level of uPA is upregulated in 15-LOX-1/PC-3 cells. (A) Comparison of expression 
of uPA in PC-3 cells versus 15-LOX-1/PC-3 cells. (B) The effect of ALOX siRNA on the 
expression of uPA in PC-3 cells and 15-LOX-1/PC-3 cells (C) The fold change in the mRNA 
level of uPA in PC-3 cells versus 15-LOX-1/PC-3 cells. 
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4.4.2. Activation of MAPK pathway in LOX-overexpressing PC-3 cells 
Studies have shown that lipoxygenases (LOXs) may act as secondary messengers and 
participate in the activation of cancer related signaling pathways, including mitogen activated 
protein kinases pathway (MAPK) [557]. There are three subfamilies of mammalian MAPKs 
which includes the extracellular signal regulated kinases (ERKs), Jun NH2-terminal kinases 
(JNK), and the p38 MAPK kinases. ERK (also known as p42/44 MAPK) is crucial for regulating 
cancer growth and differentiation, the JNK pathway plays important role in the regulation of 
stress responses and apoptosis, and the p38 MAPK is also involved in the regulation of signaling 
pathways controlling cellular responses to stress and cytokines [546]. We were particularly 
interested in investigating the total versus phosphorylated status of different MAPK subfamilies 
because it would provide us crucial information regarding further downstream signals that may 
potentially be activated. To identify whether MAPK pathway was activated in 15-LOX-1/PC-3 
cells, the level of different phosphorylated proteins of the MAPK family such as phospho-
ERK1/2 (p-ERK1/2), phospho-JNK (p-JNK), phospho-p38 MAPK (p-p38 MAPK) was 
compared in 15-LOX-1/PC-3 cells and PC-3 cells. In agreement with previous studies [558], it 
was found that there was overexpression of phosphorylated forms of ERK1/2 in 15-LOX-1/PC-3 
cell line as compared to PC-3 cells (Fig. 32A).The other two members, p38 MAPK and JNK1/2, 
were also activated as indicated by higher levels of p-p38MAPK and p-JNK1/2 proteins in PC-3-
LOX cells as compared to PC-3 cells. Therefore, these results indicated that overexpression of 
15-LOX-1 in PC-3 prostate cancer may indeed contribute to activation of mitogenic pathways 
which are implicated in cancer development. 
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Fig. 32. Role of MAPK pathway in the regulation of uPA. (A) Activation of MAPK pathway in 
15-LOX-1/PC-3 cells. Effect of MAPK inhibitors on the expression of uPA on (B) PC-3 and (C) 
15-LOX-1/PC-3 cell. 
4.4.3. Involvement of MAPK pathway in the upregulation of uPA in 15-LOX-1/PC-3 cells 
Studies have shown that MAPK activation, mediated by various signaling cascades such 
as generation of reactive oxygen species may lead to upregulation of uPA [559, 560]. To 
investigate whether the overexpression of 15-LOX-1 in PC-3 cells was associated with 
upregulation of uPA, we incubated the cells with specific inhibitors of the MAPK family such as 
ERK1/2 inhibitor U0126 (10 µM), p-38MAPK inhibitor SB203580 (10 µM), and JNK1/2 
inhibitor SP600125 (10 µM) with either PC-3 cells or PC-3-LOX cells. The cells were subjected 
to western blot analysis to assess the effect of the MAPK pathway inhibitors (Fig. 32C). We 
observed that treatment with all MAPK inhibitors significantly reduced the level of uPA in PC-3-
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LOX cell lines, with maximum inhibition observed in case of JNK1/2 inhibitor (SP600125). 
Studies have shown that the JNK pathway and p-38 MAPK pathway can be activated by 
oxidative stress. Since lipoxygenases are good candidates for generating reactive oxygen species 
[561], they may be involved in the activation of members of the MAPK family, especially the 
JNK1/2 pathway since it involved activated by stress [562].  It is worthy to note that involvement 
of JNK1/2 pathway has already been implicated in the upregulation of uPA in PC-3 cells [563]. 
In agreement with this study, we found that upon incubation of PC-3 cells with JNK1/2 inhibitor, 
there was complete suppression of uPA production. On the other hand, there was either a slight 
changes in uPA level observed in PC-3 cells when they were incubated with ERK1/2 inhibitor 
and p-p38 MAPK inhibitor respectively. Our results indicated that JNK1/2 pathway is the major 
pathway that may be at least partially involved in the upregulation of uPA in 15-LOX-1 
overexpressing PC-3 cells. 
4.4.4. Migration assay 
The level of uPA in cancer cells can influence its cell migration ability. Certain forms of 
lipoxygenases may alter cancer cell motility [513, 564], however; there are no studies so far 
which suggest that lipoxygenases may play role in uPA production. In previous section, it was 
found that transfection of 15-LOX-1 in PC-3 cells enhances the mRNA and protein levels of 
uPA.  To study whether 15-LOX-1 transfection in PC-3 cells can enhance their migration ability, 
the migration of PC-3 cells and 15-LOX-1/PC-3 cells was compared. Fetal bovine serum (10% 
v/v) was used as a chemotactant in the study. As expected, we found that 15-LOX-1/PC-3 cells 
had greater migratory potential as compared to parental PC-3 cells (p<0.05) (Fig. 33). Our results 
suggest that overexpression of 15-LOX-1 in PC-3 cells may contribute to migratory potential in 
these cells. 
96 
 
 
Fig. 33. Migration assay. Comparison of migratory potential of PC-3 cells versus 15-LOX-1/PC-
3 cells. 15-LOX-1/PC-3 cells demonstrated significantly greater migration as compared to PC-3 
cells (p<0.05). Upon incubation of 15-LOX-1.PC-3 cells with NDGA inhibitor, there was 
significant reduction in migration observed (p<0.05). 
 
4.4.5. Wound healing assay 
To compare the wound healing ability, monolayers of PC-3 cells and 15-LOX-1/PC-3 
cells were scratched with a 100 µL pipette tip. After 24 hr of wounding, a large amount of both 
the cell lines had already migrated into the wound space; however, 15-LOX-1/PC-3 cells 
demonstrated significantly greater wound healing ability (Fig. 34). Both PC-3 cells as well as 15-
LOX-1/PC-3 cells demonstrated typical features of migration, indicated by elongated 
morphology of few cells as well as their placement of longitudinal axis towards the center of the 
wound. To investigate whether the wound healing ability was contributed by 15-LOX-1 in cells, 
we incubated lipoxygenase inhibitors such as NDGA [565] as well as PD146176 [566]. It was 
found that both PC-3 cells and 15-LOX-1/PC-3 cells incubated with the inhibitors demonstrated 
decrease in wound healing ability as compared to their respective controls. These data suggested 
that 15-LOX-1 might contribute to the wound healing ability of PC-3 cells. 
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Fig. 34. Wound healing assay. (A) Kinetics (0, 12, 24 hr) of wound healing in PC-3 and 15-
LOX-1/PC-3 cells. (B) Comparison of wound healing ability in PC-3 cells and 15-LOX-1/PC-3 
cells. 
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4.5. Conclusion 
 
A variety of studies have shown that lipoxygenases are involved in diseases including 
cancer, inflammatory disorders, atherosclerosis and angiogenesis. 15-Lipoxygenase-1 (15-LOX-
1) is one of the two isoforms of 15-LOX that has been implicated to have a pro-tumorigenic role 
in prostate cancer. In the present study, we examined the relationship between the expression of 
15-LOX-1 and urokinase plasminogen activator (uPA), a serine protease which is overexpressed 
in cancer. By performing a variety of in vitro and biofunctional assays, we demonstrated that the 
overexpression of 15-LOX-1 in PC-3 cells increased the mRNA as well as protein level of uPA 
upto 5-fold and contributed to their migratory ability. The incubation of lipoxygenase inhibitor 
(NDGA) reversed this effect, and therefore decreased the migratory ability of parental as well as 
15-LOX-overexpressing PC-3 cells. In summary, our results are in agreement with the previous 
studies which suggested that 15-LOX-1 has a protumorigenic role in prostate cancer. We believe 
that investigation of 15-LOX-1 as an upstream of uPA would help in designing new strategies 
for treating prostate cancer. 
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CHAPTER 5. GENERAL CONCLUSION 
The research conducted in this thesis discusses nanotechnology-based approaches for 
diagnosis and treatment of cancer. The first two chapters in this thesis focus on conjugation of 
peptide nanofibers recombinant antibodies and near infrared dyes, whereas the third chapter 
focuses on a novel pathway involved in the tumor promoting role of 15-LOX-1 prostate cancer. 
The important conclusions drawn from research in chapter I have been listed as follows: 
 A near infrared nanofiber (NIR-NFP) for imaging urokinase plasminogen activator (uPA) 
was successfully synthesized and characterized. The NIR-NFP was (100 x 4) nm in 
dimension and contained an uPA cleavable substrate and multiple near infrared dye 
molecules. The fluorescence of nanofiber was quenched due to close proximity of near 
infrared dye molecules. Incubation with recombinant uPA in vitro resulted in about 20-
fold increase in uPA. 
 NIR-NFP was able to detect uPA secreted from different cancer cells. The levels of uPA 
detected by NIR-NFP correlated with very well with the actual uPA level of the cells (as 
confirmed by a commercial uPA activity assay kit). 
Our data in chapter I suggest that NIR-NFP can be used as a potential near infrared 
imaging agent for recombinant as well as cell-secreted uPA activity. Overall, we believe that this 
strategy has potential for designing personalized, protease-based inhibitors and prodrug targeted 
therapies in future. 
In chapter II, we demonstrate the synthesis of multivalent Herceptin conjugated 
nanofibers for increasing the therapeutic efficacy of Herceptin. Our results are: 
 A peptide nanofiber conjugated with multivalent display of antibodies was synthesized. 
Each HER-NFP contained approximately 10 Herceptin antibodies. Significant 
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improvement in therapeutic efficacy was achieved when Herceptin was displayed in 
multivalent format. HER-NFP was approximately 2.5 fold more effective in inhibiting 
cell growth as compared to unconjugated Herceptin. 
 Optimized HER-NFP preparation was able to induce HER-2 membrane receptor 
mediated internalization to downregulate its expression level to a greater extent as 
compared to Herceptin alone.  
 Along with the alteration in downstream signaling and cellular responses, the HER-NFP 
internalized to a greater extent as compared to Herceptin alone. 
Overall, our findings in chapter II provide strong evidence that this approach may be useful 
for increasing the therapeutic efficacy of monoclonal antibodies. 
The third chapter of thesis is focused on the role of 15-LOX-1 in the upregulation of uPA in PC-
3 prostate cancer cells. In this chapter, our findings are: 
 For the first time, we demonstrate that 15-LOX-1 overexpression can lead to upregulation 
uPA. Western blot analysis showed higher levels and activity of uPA in 15-LOX-1/PC-3 
cells as compared to parental PC-3 cells. 
 In vitro migration assay and wound healing assay revealed that in PC-3 cells revealed that 
15-LOX-1/PC-3 cells had greater migratory potential than PC-3 cells.  
 Upregulation of uPA in 15-LOX-1/PC-3 cells may be mediated through the activation of 
members of mitogenic activated protein kinase pathways. 
Overall, conclusions drawn from chapter III suggest that 15-LOX-1 may contribute to 
metastatic potential mediated by upregulation of uPA in prostate cancer and that targeting 15-
LOX-1 pathway may be a useful strategy for treatment and/or prevention of prostate cancer.  
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CHAPTER 6. FUTURE DIRECTIONS 
The research performed in this thesis indicates that nanofiber may serve as a diagnostic 
and drug delivery platform for the treatment and/or prevention of cancer. Since we obtained 
promising results in our preliminary in vitro studies, it would be of great interest to explore in 
vivo applications of nanofiber in xenograft model. Results from these studies so far serve as 
proof of concept for the application of this technology in future biomedical research. 
In first chapter, we demonstrated the design and synthesis of a near infrared peptide 
nanofiber probe for imaging urokinase activity. This project is ultimately aimed at improving 
individualized therapy through biomarker-driven approaches by identifying subset of patients 
that are more likely to undergo metastasis. Some prospective studies that may be included are: 
 To investigate the ability of NIR-NFP to detect tumor-secreted uPA tumor in nude mice 
by in vivo fluorescence imaging technique. 
 To compare biodistribution and pharmacokinetic profile of NIR-NFP with free dye and 
other nanomaterial. Given the unique physicochemical properties and biocompatibility, 
nanofiber may be explored as an alternate nanomaterial for clinical applications. 
In second chapter, we explore the applications of nanofiber for immuno-based treatments 
for cancer. We demonstrate that nanofiber can serve as a platform for conjugating multiple 
Herceptin antibodies. The resulting multivalent Herceptin-conjugated nanofiber showed 
significant improvement in therapeutic activity over Herceptin alone. With improvement in 
understanding additional mechanisms Herceptin, it would be interesting to perform these 
additional studies: 
 To simultaneously target multiple cellular pathways involved in cancer growth by 
combinination of HER-NFP with chemotherapy. Potential studies would involve the 
102 
 
investigation of improvement in targeting ability of anti-cancer chemotherapeutic drugs 
such as doxorubicin, ellipticine and pyrene by co-delivering with HER-NFP. 
 Another potential study would be to investigate whether HER-NFP is able to overcome 
resistance due to Herceptin in HER-2 positive cells.  
In third chapter, our studies revealed that 15-LOX-1 may lead to upregulation of uPA in PC-
3 prostate cancer cells. Based on our preliminary results, it is suggestive that targeting 15-LOX-1 
may be potential strategy in the treatment of prostate cancer. However, further studies need to 
confirm this concept in vivo. Some potential future studies for chapter III include: 
 In vivo work may be performed to confirm if there are any dietary risks factors associated 
with cancer. To achieve this, nude mice bearing either PC-3 or 15-LOX-1/PC-3 tumors 
may be utilized to compare cancer metastasis and median survival rate. Roles of LOXs 
and their metabolites can have important implications to cancer therapy. 
 To investigate other members of the lipoxygenase family which are also implicated to 
play a role in cancer development (eg. such as 5-LOX and 12-LOX) and see if similar 
relationship exists.  
 To gain further insight into association between uPA and 15-LOX-1, levels of uPA and 
15-LOX-1 in tumors obtained from prostate cancer patients would be a potential study to 
perform. 
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